

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A prospective study of factors associated with asthma attack recurrence in children from three Ecuadorian cities during Covid-19: the Asthma Attacks study (ATTACK)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056295
Article Type:	Protocol
Date Submitted by the Author:	11-Aug-2021
Complete List of Authors:	Morillo, Diana; Universidad Internacional del Ecuador Mena-Bucheli, Santiago; Universidad Internacional del Ecuador Ochoa, Angélica; Universidad de Cuenca Chico, Martha E; Universidad Internacional del Ecuador Rodas, Claudia; Universidad de Azuay Maldonado, Augusto; Universidad San Francisco de Quito; Hospital General Docente Calderón Arteaga, Karen; Hospital Verdi Cevallos Balda Rodriguez, Alejandro Figueiredo, Camila; Universidade Federal da Bahia Ardura-Garcia, Cristina; University of Bern Bachmann, Max; Univeristy of East Anglia, Norwich Medical School, University of East Anglia Perkin, Michael; St George's, Population Health Research Institute Chis Ster, Irina; St. George's University of London; St George's University of London Cruz, Alvaro; Universidade Federal da Bahia Romero, Natalia; Universidad Internacional del Ecuador, Quito, School of Medicine; Grups de Recerca d'America i Africa Llatines, GRAAL Cooper, Philip; Universidad Internacional del Ecuador; St George's University of London
Keywords:	Asthma < THORACIC MEDICINE, COVID-19, Epidemiology < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 **Title:** A prospective study of factors associated with asthma attack recurrence in
5 children from three Ecuadorian cities during Covid-19: the Asthma Attacks study
6 (ATTACK)
7
8
9

11 **Authors**

12 Diana Morillo¹, Santiago Mena-Bucheli¹, Angélica Ochoa², Martha E Chico¹, Claudia
13 Rodas³, Augusto Maldonado ^{4,5}, Karen Arteaga⁶, Alejandro Rodriguez¹, Camila
14 Figueiredo⁷, Cristina Ardura-Garcia⁸, Max Bachmann⁹, Michael Perkin¹⁰, Irina Chis
15 Ster¹⁰, Alvaro A Cruz^{7, 11}, *Natalia Romero^{1,12}, *Philip J Cooper ^{1,10}
16
17
18
19
20
21

22 **Affiliations**

23
24 ¹ Universidad Internacional del Ecuador, Quito, Ecuador.

25
26 ² Universidad de Cuenca, Cuenca, Ecuador.

27
28 ³ Universidad de Azuay, Cuenca, Ecuador

29
30 ⁴ Universidad San Francisco de Quito, Quito, Ecuador

31
32 ⁵ Hospital General Docente Calderón, Quito, Ecuador

33
34 ⁶ Hospital Verdi Cevallos Balda, Portoviejo, Ecuador

35
36 ⁷ Universidade Federal da Bahia, Salvador, Brazil

37
38 ⁸Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

39
40 ⁹ University of East Anglia, Norwich, UK.

41
42 ¹⁰ St George's University of London, London, UK.

43
44 ¹¹ProAR-Center of Excellence in Asthma, Salvador, Brazil

45
46 ¹²Grups de Recerca d'Amèrica i Àfrica Llatines GRAAL, Barcelona, Spain
47

48 *Contributed equally
49

50 **Correspondence**

51
52 Philip J. Cooper, Escuela de Medicina, Universidad Internacional del Ecuador, Av. Jorge
53 Fernández y Av. Simon Bolivar, Quito, Ecuador.
54

55 Email: pcooper@sgul.ac.uk
56

57 **Word count**

58
59
60

1
2
3
4 Abstract: 282
5 Text: 3,782
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Asthma attacks are a growing cause of morbidity in children and burden on health systems in low and middle-income countries, and there is limited information on factors associated with asthma attacks in poor urban settings in Latin America.
- This protocol describes a study designed to investigate risk factors associated with recurrence of asthma attacks in children and adolescents living in marginalized settings in three Ecuadorian cities.
- This study is recruiting children and adolescents with uncontrolled asthma symptoms and asthma attacks and following them prospectively for 6 to 12 months to identify factors associated with recurrence of attacks in the context of the Covid-19 pandemic.
- The Covid-19 pandemic has had a major impact on health seeking behaviours while mitigation strategies to control transmission of the novel coronavirus, SARS-CoV-2, have resulted in marked declines in the circulation of respiratory viruses that are considered to underlie a high proportion of asthma attacks. Such factors may interfere with recruitment and follow-up of study participants.

Abstract

Introduction: Asthma is a growing health problem in children living in marginalized urban settings in low and middle-income countries. Asthma attacks are an important cause of emergency care attendance and long-term morbidity. We designed a prospective study, the Asthma Attacks study (ATTACK), to identify factors associated with recurrence of asthma attacks among children and adolescents attending emergency care in three Ecuadorian cities.

Methods and analysis: Prospective clinical cohort study designed to identify risk factors associated with recurrence of asthma attacks (or exacerbations) in 450 children and adolescents aged 5 to 17 years attending emergency care in public hospitals in three Ecuadorian cities (Quito, Cuenca, and Portoviejo). The primary outcome will be rate of asthma attack recurrence during 6 to 12 months of follow-up. Data are being collected at baseline and during follow-up by questionnaire: sociodemographic data, asthma history and management (baseline only); recurrence of asthma symptoms and attacks (monthly); economic costs of asthma to family; Asthma Control Test; Pediatric Asthma Quality of life Questionnaire; and Newcastle Asthma Knowledge Questionnaire (baseline only). In addition, the following are being measured at baseline and during follow-up: lung function and reversibility by spirometry before and after salbutamol; fractional exhaled nitric oxide (FeNO); and presence of IgG antibodies to SARS-CoV-2 in blood. Recruitment started in 2019 but because of severe disruption to emergency health services caused by the Covid-19 pandemic, eligibility criteria were modified to include asthmatic children with uncontrolled symptoms and registered with collaborating hospitals. Data will be analysed using logistic regression and survival analyses.

Ethics and dissemination: The study results will be disseminated through presentations at conferences and to key stakeholder groups including policy makers, postgraduate student theses, peer-review publications, and on a study website.

Introduction

Asthma is the most common chronic disease of childhood and is estimated to affect more than 350 million people worldwide [1]. Although initially described as a disease of high-income countries (HICs) such as the United Kingdom, international comparisons using standardized methodologies have shown a similar or greater prevalence among children in urban centres in Latin America as observed in HICs [2]. There is evidence that the prevalence of asthma has increased in low- and middle-income countries (LMICs) over recent decades [2].

Asthma attacks or exacerbations are frequent in children and are a common cause of hospitalization [3], most frequently associated with respiratory viral infections [4], but also with exposures to allergens [5] and air pollution [6] among individuals with an underlying genetic susceptibility [7]. Asthma is an underdiagnosed disease because of lack of specialized personnel and resources to evaluate lung function. Further, limited access to specialized care and treatment [8], accompanied by poor treatment adherence [9,10] are important contributing factors to inadequate disease control and attacks, especially in underprivileged populations. In such settings, asthma patients with poor control of their daily symptoms often rely on emergency room care for management of their symptoms [11], resulting in high economic costs to health systems and patients' families [8,12].

To understand better factors contributing to the risk of asthma attacks, it is important identify those factors contributing to suboptimal management which can be improved through better health care [13]. Several studies have investigated potential predictors of recurrence of asthma attacks among children attending emergency services. Factors identified as important included a history of previous emergency attendances for acute asthma attacks, younger age [13–15], ethnicity of African descent [16,17], and low socioeconomic status [13,18]. These studies were conducted almost exclusively in North America and frequently included adult Hispanic populations living there. There are relatively few such studies done in LMICs [13,16,18].

1
2
3
4 The Asthma Attacks Study (ATTACK) aims to identify factors related to recurrence of
5 asthma attacks in Ecuadorian children attending emergency care in three Ecuadorian
6 cities. Recruitment into the study started in March 2019 but was interrupted by the
7 Covid-19 pandemic that had a major impact on use of and access to emergency care
8 [19]. In consequence, the original protocol was modified to allow continued
9 recruitment and measure the impact of the Covid-19 pandemic and exposures to SARS-
10 CoV-2 on asthma attacks in children and adolescents.
11
12
13
14
15
16
17
18

19 *What is known about factors related to asthma attacks and impact of COVID-19*
20 *pandemic?*
21

22 Severe asthma in children is associated with loss of lung function [20], as well as with
23 high costs of medical and family care [2]. In Latin America, asthma has been described
24 as a major public health problem because of a high prevalence and significant
25 associated morbidity and mortality [21]. Asthma control among children in Latin
26 America has been reported to be among the worse worldwide [22–25]. The Latin
27 America Asthma Insights and Management study reported adequate asthma control
28 in less than 20% of asthmatic children in Argentina, Brazil, Mexico, Venezuela, and
29 Puerto Rico [22]. A case-control study of asthmatic children with an acute attack
30 attending an Emergency Room (ER) in coastal Ecuador showed that, over the previous
31 12 months, only 20% of children had visited a doctor in the past year, 86% had
32 attended an emergency room at least once prior, and none were receiving inhaled
33 corticosteroids despite over half having suffered four or more acute exacerbations
34 [26]. A previous prospective study of children with asthma attacks in coastal Ecuador
35 showed a recurrence rate of 46% within 6 months [13].
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Asthma attacks represent an acute or subacute increase in respiratory symptoms [25]
51 and severe attacks - defined as requiring ER or hospital care and treatment with
52 systemic corticosteroids for at least 3 days - are associated with loss of lung function
53 [20] and high economic costs to the patient's family and health care system [7], as well
54 as absenteeism in work and school.
55
56
57
58
59
60

1
2
3
4 Asthma attacks may be prevented either by avoiding previously identified triggers or
5
6 by appropriate preventive treatment. Patients using inhaled corticosteroids (ICS) were
7
8 3 times more likely to have well-controlled asthma [22], a reduction in symptoms
9
10 independent of frequency, and better lung function [1]. In Brazil, preventive strategies
11
12 have been successfully implemented through asthma control programs such as Pro-AR
13
14 in Salvador de Bahía to reduce future risk in asthmatic patients from less privileged
15
16 backgrounds, through the provision of ICS [27]. There has been a shift to using ICS more
17
18 widely for control of asthma, for example, through the provision of combination
19
20 inhalers including both ICS and a beta₂ agonist for moderate to severe asthma [28].
21
22 More recent evidence indicate that the use of ICS may be beneficial even for asthmatic
23
24 children with mild disease that accounts for 30-40% of severe attacks [29]. Treatment
25
26 recommendations for children and adolescents with mild disease are now shifting to
27
28 use of ICS (plus long-acting beta-agonists in combination inhalers) as required [30,31].
29
30 Despite such initiatives, access to ICS in many LMIC settings is limited within health
31
32 care systems because of cost and a failure to recognize the public health impact of
33
34 childhood asthma. In such settings, children with asthma symptoms frequently over-
35
36 rely on ER care for the acute control of their symptoms in the absence of adequate
37
38 provision of specialized care for their long-term management [26,32].

39
40 Soon after the emergence of the novel coronavirus, SARS-CoV-2, in humans and its
41
42 spread into a global pandemic, the question was raised as to whether this novel viral
43
44 infection might alter the risk of asthma symptoms because of deficient antiviral
45
46 immune responses and the tendency to increase exacerbations during infections with
47
48 other respiratory viruses [33]. To date, evidence from studies of asthmatic children and
49
50 adults do not indicate an increased risk [34,35]. Characteristics of asthmatic airways
51
52 among those with T2-linked phenotypes may reduce the expression of the cellular
53
54 receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), in the airways [36].
55
56 It has been suggested that the use of ICS among asthmatics may reduce risk of severe
57
58 Covid-19 by suppressing inflammation and enhancing antiviral defenses [37], although
59
60 the evidence remains unclear [38] and there are very limited data from pediatric
populations [38]. The Covid-19 pandemic has resulted in marked reductions in hospital

1
2
3
4 visits including to emergency rooms (Figure 1), reduced attack rates, and better lung
5 function among children with asthma [19,39], which are likely consequences of
6 mitigation measures to reduce transmission of SARS-CoV-2 (such as lockdowns, face
7 masks, and social distancing) that have resulted also in the reduced transmission of
8 other respiratory viruses [4,6,10,39]. Treatment adherence may have improved also
9 because of better parental supervision of asthma medications [40]. There are limited
10 data on the impact of exposure to SARS-CoV-2 on asthma attacks and uncontrolled
11 symptoms and the impact of the collateral effects of the Covid-19 pandemic including
12 reduced access to health services and medications and effects of Covid-19 mitigation
13 efforts in resource-poor LMIC settings.
14
15
16
17
18
19
20
21
22
23

24 **Figure 1: Impact of the COVID-19 pandemic in the 3 study centres in Quito, Portoviejo**
25 **and Cuenca, Ecuador, on recruitment rates into the study and number of potentially**
26 **eligible subjects identified in collaborating emergency rooms. Red bars show**
27 **numbers recruited as a proportion (%) of those eligible (blue bars) prior to a legally**
28 **enforced national lockdown on 16th March 2020.**
29
30
31
32
33

34 **Methods and analysis**

35 *The Asthma Attack study*

36
37 A prospective multi-center study is being done in children aged 5 to 17 years in low-
38 income settings in three Ecuadorian cities (Quito, Cuenca, and Portoviejo) to study
39 factors associated with acute asthma attacks. Because of the impact of the Covid-19
40 pandemic on risk of asthma attacks and health care access, the study was divided into
41 2 phases of recruitment and follow-up: 1) Phase I (or pre-Covid-19 from May 2019 to
42 March 2020) evaluated risk factors associated with recurrence of acute asthma attacks
43 among children and adolescents attending emergency rooms of public hospitals in low-
44 income settings in the three cities; and 2) Phase II (or peri-COVID-19 from March 2021
45 to March 2022) is evaluating risk factors associated with attacks among children and
46 adolescents with asthma and current symptoms who have previously attended
47 specialist care at public hospitals in Cuenca and Portoviejo. Phase II is also evaluating
48 the effects of exposures to SARS-CoV-2 on asthma attacks and symptoms. In addition,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 both study phases are evaluating the impact of asthma, and adequate management
5 and control of asthma, on the quality of life and economic costs for the family of
6 children and adolescents with asthma. Qualitative studies of health worker's
7 perspectives on asthma care coordination between primary and specialized health
8 care are being done also as described elsewhere.
9
10
11
12
13
14

15 *Study design and setting*

16 This is a multi-center prospective study conducted in three Ecuadorian cities (Quito,
17 Cuenca, and Portoviejo). Quito, the capital, and Cuenca, the third largest city, are
18 located in the Andean highlands (altitude >2,500m) where the annual average
19 temperature is ~16°C, while Portoviejo is in the coastal region (at sea level) with an
20 annual average temperature of ~25 °C [41]. According to the 2010 census, the
21 populations of the three cities are: Quito >2 million, Cuenca 0.5 million, and Portoviejo
22 0.28 million inhabitants. Ecuador is an upper-middle-income-country with a per capita
23 income of \$6,080 in 2019. The health system in Ecuador includes public and private
24 provision. Public institutions offer universal health coverage that is stratified into
25 different levels of care from primary to tertiary services [42]. Social security institutions
26 offer health services to affiliated salaried workers and their families. The private sector
27 includes for-profit entities (hospitals, clinics, dispensaries, doctor's offices, pharmacies,
28 and prepaid health insurance companies) which are generally located in the main cities
29 [43].
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 *Study centers*

46 The study was initially based in the tertiary care hospitals in each of the three cities
47 (Hospital Docente General de Calderon, Quito; Hospital Vicente Corral Moscoso,
48 Cuenca; and Hospital Verdi Cevallos Balda, Portoviejo).
49
50
51
52
53

54 *Recruitment - Phase I (pre-COVID-19; May 2019 to March 2020)*

55 Children and adolescents aged 5–17 years were either recruited, either while attending
56 emergency rooms (ERs) with an asthma attack or through daily registries and contact
57 telephone numbers of patients attending the ERs with an asthma attack. From May
58
59
60

2019, eligible patients (Table 1) were provided with a study information sheet on discharge and their parents were contacted to arrange an interview at a hospital consulting room 10-14 days later when they were recruited into the study after providing informed written parental consent and minor assent (8 years and older).

Recruitment – Phase II (peri-COVID-19; March 2021 to March 2022)

The Covid-19 pandemic had a dramatic impact on our ability to recruit children with asthma attacks in the three study hospitals that resulted in the suspension of recruitment in March 2020. This was owing to the reassignment of all 3 hospitals to Covid-19-only activities for prolonged periods and the imposition of a legally enforced lockdown nationally. Figure 2 shows the number of potentially eligible children identified in the 3 study hospitals by month in the period prior to Covid-19 and during the pandemic. There was as a marked reduction in eligible children attending the ERs immediately following the imposition of lockdown on 16th March 2020 and in the following 8 months. In the period following the initial lockdown and other mitigation strategies to reduce transmission of SARS-CoV-2, within the sample of asthmatic children recruited into Phase I of the study, there was evidence of dramatic reduction in health service attendance rather than changes in the incidence of attacks [19]. To allow continued recruitment, a second phase (Phase II) of the study was started with eligibility criteria modified to include children and adolescents aged 5-17 years registered as having asthma in patient registries at the study hospitals in Cuenca and Portoviejo (Quito was not included in Phase II because of logistic issues in that specific setting). The child's parent was contacted by telephone and asked about the child's current asthma symptoms. Children with current symptoms were considered eligible. Eligibility criteria for Phase I and II are shown in Table 1.

Table 1 Eligibility criteria for entry into Phase I and Phase II of study

Characteristic	Phase I	Phase II
Setting/study population	Public hospital ERs in Quito, Cuenca, and Portoviejo	Public hospital registry of patients with asthma in Cuenca and Portoviejo

Inclusion criteria	<ol style="list-style-type: none"> 1. Aged 5-17 years 2. Acute asthma attack attending ERs at public hospitals 3. Living within 12 km of public hospital 4. Informed written consent from parents 5. Minor assent from children ≥ 8 years 	<ol style="list-style-type: none"> 1. Aged 5-17 years 2. Wheeze within the last 6 months 3. Living within 12 km of public hospital 4. Informed written consent from parents 5. Minor assent from children ≥ 8 years
Exclusion criteria	<ol style="list-style-type: none"> 1. Other chronic disease 2. Living >12 km from public hospital 	<ol style="list-style-type: none"> 1. Other chronic disease 2. Living >12 km from public hospital

Data collection

A study manager supervised day-to-day activities of a dedicated teams (physician and nurse) of trained study personnel based in each of the public hospitals. Each participant was followed up for 12 months in Phase I and at least 6 months in Phase II. Standardized procedures were used throughout (Figure 2). Subjects were evaluated at monthly intervals using face-to-face and telemonitoring for follow-up. Both phases include face-to-face evaluations (evaluations at baseline, 2, 4, 6, 9, and 12 months in Phase I; baseline, 6, and 12 months in Phase II). Between March 2020 and March 2021, all face-to-face evaluations in Phase I were changed to telemonitoring apart from the final evaluation at 12 months which remained face-to-face, where possible. Final face-to-face evaluations were done in March-April 2021 on participants who had completed 12 months of follow-up between June 2019 and February 2020. The site of face-to-face evaluations was changed to either a clinic or home visit depending on the preference of the child's parents. Study procedures were the same in both phases of the study (Figure 2) with the following exceptions: 1) procedures requiring face-to-face evaluations at 6 and 12 months in Phase I (C-ACT, and PAQLQ) were dropped in Phase II and the remaining instruments were administered by telemonitoring; 2) blood samples (baseline, 6, and 12 months) are being collected from those recruited into Phase II of the study for measurement of anti-SARS-CoV-2 IgG antibodies; and 3)

1
2
3
4 measurement of lung function and fractional exhaled nitric oxide was suspended from
5 March 2020 because of risks from potentially hazardous infectious aerosols until a time
6 when this procedure can be done safely. Medications (inhaled salbutamol and
7 fluticasone) were provided free of charge to participants when prescribed by a hospital
8 physician and there was no medication in the hospital pharmacy. The study team
9 ensured adequate inhaler technique during face-to-face clinic or home visits. Study
10 personnel did not interfere with treatment indications of hospital staff.
11
12
13
14
15
16
17
18

19 **Figure 2. Study procedures during baseline evaluation and follow-up in Phases I (A)**
20 **and II (B) of study.**

21
22 **BaselineQ – General questionnaire based on Phase II of the International Study of**
23 **Asthma and Allergies in Childhood; AFCQ- Asthma Family Costs Questionnaire; NAKQ**
24 **– Newcastle Asthma Knowledge Questionnaire; ACT – Asthma Control Questionnaire**
25 **(>11 years); C-ACT – Child Asthma Control Questionnaire (>=12 years); ARQ – Asthma**
26 **Recurrence Questionnaire; FeNO – fractional exhaled nitric oxide. Follow-up in Phase**
27 **I was for 12 months and in Phase II for a minimum of 6 months.**
28
29
30
31
32
33
34
35
36

37 *Questionnaires at baseline and follow-up*

38
39 The following questionnaires were used as indicated in Figure 2; i) asthma
40 questionnaire to collect information on history of asthma symptoms, treatment and
41 management, and potential risk factors for asthma attacks. This questionnaire has
42 been previously adapted from ISAAC Phase II and extensively field-tested for children
43 and adolescents with asthma [13,26]; ii) Asthma Recurrence Questionnaire (ARQ) -
44 questionnaire to monitor recurrence of asthma symptoms and monitor treatment
45 during follow-up [13], and including symptoms and diagnosis of Covid-19 in Phase II;
46 iii) Childhood Asthma Control Test (C-ACT) [44], completed by the child and parent for
47 children aged <12 years or the ACT [45] for those aged ≥12 years; iv) Paediatric Asthma
48 Quality of Life Questionnaire (PAQLQ) [46]; v) Newcastle Asthma Knowledge
49 Questionnaire (NAKQ) [47,48] validated in a Spanish-speaking populations; and vi)
50
51
52
53
54
55
56
57
58
59
60

Asthma Family Cost Questionnaire (AFCQ) [49]. Data collection is summarized in Table 2.

Table 2 Data collection at baseline and during follow-up in Phases I and II of study

Data collected	Baseline	Month 6	Month 12	Monthly
Asthma diagnosis	I/II			
History of asthma symptoms	I/II			
Current asthma symptoms	I/II	I/II	I/II	I/II
ER visits/ hospitalizations	I/II	I/II	I/II	I/II
Asthma medications	I/II	I/II	I/II	I/II
Asthma control (C-ACT/ACT)	I/II	(I)/II	(I)/II	
Asthma quality of life (PAQLQ)	I/II	(I)/II	(I)/II	
Asthma knowledge (NAKQ)	I			
Lung function	I/(II)	(I/II)	(I)	
Reversibility	I/(II)	(I/II)	(I)	
FeNO	I/II	(I)/II	(I)/II	
Anti-SARS-CoV-2 IgG antibodies	II	II	II	
Covid-19 symptoms or diagnosis	II	II	II	II

FeNO – fractional exhaled nitric oxide. (I) – data collection where possible

Lung function test and Fractional Exhaled Nitric Oxide (FeNO)

Lung function testing is being done according to American Thoracic Society (ATS) criteria using a portable ultrasonic spirometer (EasyOne® device, ndd Medical Technologies). Global Lung Function Initiative (GLI-2012) reference values will be used

1
2
3
4 to calculate z-scores depending on age, sex, height, and ethnicity [50]. Lung function is
5 being measured before and before and after 200 ug salbutamol administered through
6 a spacer with a positive test for airways reactivity defined as an increase in FEV₁ of
7
8 ≥12%. Fractional exhaled nitric oxide (FeNO) is being measured in parts per billion
9
10 using NObreath (Bedfont Scientific, UK). As a consequence of lockdown and mitigation
11
12 strategies to prevent transmission of SARS-CoV-2, measurement of lung function and
13
14 FeNO was suspended in March 2020. FeNO measurement, a low effort procedure that
15
16 carries a minimal risk of generating aerosols [51,52], was resumed in March 2021 for
17
18 12-month evaluations in Phase I and baseline evaluations in Phase II. FeNO is being
19
20 done following the recommendations of the manufacturer to minimize potential risks
21
22 [53]. Spirometry, which often induces cough, will be resumed, only if the procedure
23
24 can be done without risk to staff, patients, and their families.
25
26
27

28 *Blood samples*

29
30 Blood sample are being taken at baseline, 6 and 12 months in Phase II. Blood is drawn
31
32 from an antecubital vein into a 4 mL plastic tube containing EDTA as anticoagulant
33
34 (Vacutainer, BD). After centrifugation, plasma is stored at -20C until analysis. Levels of
35
36 IgG specific for SARS-CoV-2 are being measured using a validated enzyme linked
37
38 immunosorbent assay [54].
39
40

41 *Biosafety precautions relating to the COVID-19 pandemic*

42
43 Personnel gathering data during face-to-face visits have been trained to use
44
45 appropriate personal protective equipment according to international guidelines
46
47 [55–57]. Immediately prior to a home or clinic visit, the child’s carer is telephoned
48
49 about potential symptoms or a COVID-19 diagnosis among family members or close
50
51 contacts – if any symptoms are reported the visit is rescheduled after 2 weeks.
52
53

54 *Sample size considerations*

55
56 A sample size of 450 patients was proposed for Phase I, based on a binary outcome
57
58 variable for recurrence of an asthma attack within 12 months, or not, with an
59
60 estimated recurrence rate of about 50% during 6 months follow-up in a similar

1
2
3
4 population in Ecuador [13]. This sample size gives a power of 80% or more, based on
5 having a minimum of 18 outcome events per explanatory variable (10 or fewer
6 variables to explain variability in the outcome), allowing for 20% attrition [58–61].
7
8 Because we do not expect a multivariable model to exceed 10 predictors, the initial
9 sample size estimation is unchanged. The definition of an asthma attack in both phases
10 of the study is an episode of acute wheezing requiring an unscheduled visit to a health
11 professional (including visits to ERs) and which is controlled by β_2 -agonist
12 bronchodilator treatment. The original definition for an asthma attack in Phase I that
13 included ER attendance had to be modified in the light of changes in health seeking
14 behaviour caused by the COVID-19 pandemic and fear of contagion in hospitals and
15 other acute health facilities [19]. Potential explanatory variables include age, gender,
16 ethnicity, socioeconomic status, medication use, asthma attacks and use of systemic
17 corticosteroids in year prior to recruitment, asthma control test score, and study
18 centre. Given changes to the Phase I protocol, an additional variable (for recruitment
19 from ERs vs. hospital lists) will be considered as an effect modifier. Sub-group analyses
20 of Phase II will include SARS-CoV-2 seropositivity as an explanatory variable. Secondary
21 outcomes will include symptom severity and asthma control score.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 *Statistical analysis*

38
39 The primary outcome will be the first asthma attack recurrence during 12 months of
40 follow-up in Phase I and at least 6 months in Phase II. Both logistic regression and
41 survival analyses will be used. For the latter, if no re-attendance related to an asthma
42 attack occurred during the follow-up period, the patient is considered (right) censored.
43 The general assumption for time-to-event (survival analysis) is that the censoring is
44 non-informative, i.e. it is independent of the events (asthma attacks). Under this
45 assumption, the results should not be qualitatively different from those inferred from
46 a logistic regression. Odds ratios and/or hazard ratios will measure the associations
47 between asthma attack recurrence and explanatory variables.
48
49
50
51
52
53
54

55 The Cox proportional hazard (PH) semi-parametric technique allows no assumption to
56 be made on the baseline hazard; nevertheless, proportionality of the hazards should
57 hold. The latter assumption can be tested on the basis of Schoenfeld residuals after
58
59
60

1
2
3
4 fitting models to the data. If unsatisfactory, alternative parametric models will be
5 considered after understanding the distributional assumptions on the data such that
6 the baseline hazard function is modelled appropriately.
7
8

9
10 After exploring the data as described above, a forward-backward elimination survival
11 analysis would be applied to determine the most parsimonious model for an adjusted
12 multivariable model; that is the model with the least number of predictors yet
13 explaining most of the variability in the data. Penalized-likelihood criteria such as AIC
14 or BIC will be used to choose between non-nested models – nevertheless based on
15 complete observations only.
16
17

18
19 Hosmer-Lemeshow measure of goodness of fit would be employed for logistic
20 regression models with a p-value of less than 0.05 indicating a poor fit to the data.
21 Model validation will be done by splitting the data set into training-testing subsets
22 (logistic regression setting). Cross validation techniques will be used to understand the
23 prediction power of the corresponding logistic regression model using area under the
24 receiver operator curve, prior to propose the model entering the clinical practice with
25 the view of elaborating a prognostic model. In survival setting it is also possible that
26 the precise time of the attacks may be missed but recorded as between two time
27 points. This would fall into interval censored data as an alternative to survival setting
28 in which the precise time of the event is required.
29
30

31
32 Multiple recurrences of asthma attacks within the follow-up period will generate a
33 longitudinal binary outcome, with multiple records for each participant over follow-
34 up. The hierarchical structure of the data requires special inferential techniques which
35 account for the two sources of variability: that of between participants and within
36 participants. Three different modelling approaches will be considered: generalized
37 estimation equation, mixed models, and random effects survival models. The first
38 approach provides population-average estimates, the second provides subject-specific
39 estimates while the third is also known as shared frailty survival model. A frailty is a
40 latent random effect which enters multiplicatively on the hazard function and accounts
41 for the multiple failures setting and/or for the clustered aspect of the data.
42
43

44
45 Complete data analyses will be done under missing completely at random
46 assumptions. However, patterns in missing data will be explored and methods to
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 evaluate potential impact of missing data on estimates will be used as appropriate such
5 as multiple imputations using chained equations (MICE) accompanied by a sensitivity
6 analysis to the missing data assumptions [62–64].
7
8

9
10 Analyses will use STATA (StataCorp. 2017. Stata Statistical Software: Release 15.
11 College Station, TX: StataCorp LLC) or R (R Core Team (2013)).
12
13

14 15 **Discussion**

16
17 The prevalence of childhood asthma has increased in many LMICs over the past 50 or
18 so years where asthma attacks are a growing burden to health systems [2]. There are
19 limited data on determinants of asthma attacks in children and adolescents from LMIC
20 settings [18], and a need for prospective studies to identify risk factors for asthma
21 attacks so that the limited resources available in low-resource settings can be focused
22 on those children most likely to suffer recurrent attacks to reduce morbidity and
23 economic costs to health systems and patients' families. The Asthma ATTACK study
24 aims to identify risk factors associated with asthma attacks among children and
25 adolescents attending emergency rooms in public hospitals in three Ecuadorian cities.
26
27
28
29
30
31
32
33

34
35 This study provides a range of climatic settings in Ecuador from high altitude (Cuenca
36 and Quito) to sea level (Portoviejo). Study activities were interrupted in March 2020
37 by the Covid-19 pandemic resulting in a suspension of recruitment in hospital ERs
38 owing to dramatic changes in access to and use of health facilities. As a consequence,
39 the study protocol was modified to allow re-initiation of recruitment and also the
40 evaluation of the effect of exposures to SARS-CoV-2 on risk of asthma attacks and
41 symptoms in children. The study will help fill an unmet knowledge gap on the effects
42 of SARS-CoV-2 on pediatric asthma, particularly from low-resource LMIC settings [19].
43
44
45
46
47
48
49
50

51 **Ethics and dissemination**

52
53 Ethical approval for Phase I was obtained from the Ethics Committee of the Hospital
54 General Docente de Calderon (CEISH-HGDC 2019-001) and for Phase II from the
55 Ecuadorian Ministry of Public Health COVID-19 Ethics Committee (MSP-CGDES-2021-
56 0041-O N° 096-2021).
57
58
59
60

References

1. Reddel HK, Busse WW, Pedersen S, Tan WC, Chen Y-Z, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. *Lancet*. 2017;389: 157–166.
2. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2007;62: 758–766.
3. Hasegawa K, Bittner JC, Nonas SA, Stoll SJ, Watase T, Gabriel S, et al. Children and Adults With Frequent Hospitalizations for Asthma Exacerbation, 2012-2013: A Multicenter Observational Study. *J Allergy Clin Immunol Pract*. 2015;3: 751–8.e1.
4. Deschildre A, Pichavant M, Engelmann I, Langlois C, Drumez E, Pouessel G, et al. Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients. *Respir Res*. 2017;18: 191.
5. Murray CS, Foden P, Sumner H, Shepley E, Custovic A, Simpson A. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers. *Am J Respir Crit Care Med*. 2017;196: 150–158.
6. Taquechel K, Diwadkar AR, Sayed S, Dudley JW, Grundmeier RW, Kenyon CC, et al. Pediatric Asthma Health Care Utilization, Viral Testing, and Air Pollution Changes During the COVID-19 Pandemic. *J Allergy Clin Immunol Pract*. 2020;8: 3378–3387.e11.
7. Bønnelykke K, Sleiman P, Nielsen K, Kreiner-Møller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. *Nat Genet*. 2014;46: 51–55.
8. Fischer GB, Sarria EE, Camargos P, Mocelin HT, Soto-Quiroz M, Cruz AA, et al. Childhood asthma in low and middle-income countries: Where are we now? *Paediatr Respir Rev*. 2019;31: 52–57.
9. Carroll WD, Wildhaber J, Brand PLP. Parent misperception of control in childhood/adolescent asthma: the Room to Breathe survey. *Eur Respir J*. 2012;39: 90–96.
10. Vervloet M, van Dijk L, Spreeuwenberg P, Price D, Chisholm A, Van Ganse E, et al. The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. *J Allergy Clin Immunol Pract*. 2020;8:

- 626–634.
11. Fleming L. Asthma exacerbation prediction: recent insights. *Curr Opin Allergy Clin Immunol*. 2018;18: 117–123.
 12. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract*. 2017;3: 1.
 13. Ardura-Garcia C, Arias E, Hurtado P, Bonnett LJ, Sandoval C, Maldonado A, et al. Predictors of severe asthma attack re-attendance in Ecuadorian children: a cohort study. *Eur Respir J*. 2019;54. doi:10.1183/13993003.02419-2018
 14. Smiley M, Sicignano N, Rush T, Lee R, Allen E. Outcomes of follow-up care after an emergency department visit among pediatric asthmatics in the military health system. *J Asthma*. 2016;53: 816–824.
 15. Beck AF, Simmons JM, Huang B, Kahn RS. Geomedicine: area-based socioeconomic measures for assessing risk of hospital reutilization among children admitted for asthma. *Am J Public Health*. 2012;102: 2308–2314.
 16. Zipkin R, Schragger SM, Nguyen E, Mamey MR, Banuelos I, Wu S. Association between pediatric home management plan of care compliance and asthma readmission. *J Asthma*. 2017;54: 761–767.
 17. Moncrief T, Beck AF, Simmons JM, Huang B, Kahn RS. Single parent households and increased child asthma morbidity. *J Asthma*. 2014;51: 260–266.
 18. Ardura-Garcia C, Stolbrink M, Zaidi S, Cooper PJ, Blakey JD. Predictors of repeated acute hospital attendance for asthma in children: A systematic review and meta-analysis. *Pediatr Pulmonol*. 2018;53: 1179–1192.
 19. Ochoa-Avilés AM, Ochoa-Avilés C, Morillo-Argudo DA, Molina-Cando MJ, Rodas-Espinoza CR, Chis Ster I, et al. Impact of COVID-19 pandemic on asthma symptoms and management: A prospective analysis of asthmatic children in Ecuador. *World Allergy Organ J*. 2021;14: 100551.
 20. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N Engl J Med*. 2016;374: 1842–1852.
 21. Forno E, Gogna M, Cepeda A, Yañez A, Solé D, Cooper P, et al. Asthma in Latin America. *Thorax*. 2015;70: 898–905.
 22. Alith MB, Gazzotti MR, Nascimento OA, Jardim JR. Impact of asthma control on different age groups in five Latin American countries. *World Allergy Organ J*. 2020;13: 100113.
 23. Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and

- 1
2
3
4 health care utilization in Asia-Pacific countries. *Respir Med.* 2014;108: 271–277.
5
6
7 24. Sastre J, Fabbri LM, Price D, Wahn HU, Bousquet J, Fish JE, et al. Insights,
8 attitudes, and perceptions about asthma and its treatment: a multinational
9 survey of patients from Europe and Canada. *World Allergy Organ J.* 2016;9: 13.
10
11 25. Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in
12 Australia: a cross-sectional web-based survey in a nationally representative
13 population. *Medical Journal of Australia.* 2015. pp. 492–496.
14 doi:10.5694/mja14.01564
15
16
17 26. Ardura-Garcia C, Vaca M, Oviedo G, Sandoval C, Workman L, Schuyler AJ, et al.
18 Risk factors for acute asthma in tropical America: a case-control study in the City
19 of Esmeraldas, Ecuador. *Pediatric Allergy and Immunology.* 2015. pp. 423–430.
20 doi:10.1111/pai.12401
21
22
23 27. Cruz AA, Souza-Machado A, Franco R, Souza-Machado C, Ponte EV, Santos PM,
24 et al. The Impact of a Program for Control of Asthma in a Low-Income Setting.
25 *World Allergy Organization Journal.* 2010. pp. 167–174.
26 doi:10.1097/wox.0b013e3181dc3383
27
28
29 28. Cusack RP, Satia I, O’Byrne PM. Asthma maintenance and reliever therapy:
30 Should this be the standard of care? *Ann Allergy Asthma Immunol.* 2020;125:
31 150–155.
32
33
34 29. Abrams EM, Becker AB, Szeffler SJ. Paradigm Shift in Asthma Therapy for
35 Adolescents: Should It Apply to Younger Children as Well? *JAMA pediatrics.*
36 2020. pp. 227–228.
37
38
39 30. Abrams EM, Shaker M, Greenhawt M, Fernandes RM, Sinha I. Treatment of mild-
40 to-moderate asthma in childhood and adolescence in 2021. *Lancet Respir Med.*
41 2021;9: 443–445.
42
43 31. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al.
44 GINA 2019: a fundamental change in asthma management: Treatment of
45 asthma with short-acting bronchodilators alone is no longer recommended for
46 adults and adolescents. *Eur Respir J.* 2019;53. doi:10.1183/13993003.01046-
47 2019
48
49
50 32. Neffen H, Chahuàn M, Hernández DD, Vallejo-Perez E, Bolivar F, Sánchez MH, et
51 al. Key factors associated with uncontrolled asthma – the Asthma Control in
52 Latin America Study. *Journal of Asthma.* 2020. pp. 113–122.
53 doi:10.1080/02770903.2018.1553050
54
55
56 33. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin*
57 *Rev Allergy Immunol.* 2020;59: 78–88.
58
59
60 34. Wang Y, Ao G, Qi X, Xie B. The association between COVID-19 and asthma: A

- 1
2
3
4 systematic review and meta-analysis. *Clinical & Experimental Allergy*. 2020. pp.
5 1274–1277. doi:10.1111/cea.13733
6
7
8 35. Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, et al.
9 Asthma and COVID-19: review of evidence on risks and management
10 considerations. *BMJ Evid Based Med*. 2020. doi:10.1136/bmjebm-2020-111506
11
12 36. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al.
13 COVID-19-related Genes in Sputum Cells in Asthma. Relationship to
14 Demographic Features and Corticosteroids. *Am J Respir Crit Care Med*.
15 2020;202: 83–90.
16
17
18 37. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al.
19 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
20 HCoV-229E replication and cytokine production by primary cultures of human
21 nasal and tracheal epithelial cells. *Respir Investig*. 2020;58: 155–168.
22
23
24 38. Schultze A, Douglas I. COVID-19 and inhaled corticosteroids—another piece in
25 an expanding puzzle. *The Lancet Respiratory Medicine*. 2021. pp. 674–675.
26 doi:10.1016/s2213-2600(21)00076-x
27
28
29 39. Papadopoulos NG, Mathioudakis AG, Custovic A, Deschildre A, Phipatanakul W,
30 Wong G, et al. Childhood asthma outcomes during the COVID-19 pandemic:
31 Findings from the PeARL multi-national cohort. *Allergy*. 2021;76: 1765–1775.
32
33
34 40. Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. Changes in
35 medication adherence among patients with asthma and COPD during the
36 COVID-19 pandemic. *J Allergy Clin Immunol Pract*. 2020;8: 2384–2385.
37
38
39 41. Instituto Nacional de Meteorología e Hidrología. Anuario Meteorológico Nro. 53-
40 2013. Quito, Ecuador: INAMHI; 2015.
41
42 42. Ministerio de Salud Pública. Manual del modelo de atención integral del sistema
43 nacional de salud familiar comunitario e intercultural (MAIS-FCI). Ecuador: MAIS-
44 FCI; 2012 [cited 22 Apr 2021]. Available:
45 <https://es.scribd.com/document/338645477/Manual-MAIS-MSP12-12-12-pdf>
46
47 43. Lucio R, Villacrés N, Henríquez R. Sistema de salud de Ecuador. *Salud pública de*
48 *México*. 2011;53: s177–s187.
49
50
51 44. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development
52 and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy*
53 *Clin Immunol*. 2007;119: 817–825.
54
55
56 45. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al.
57 Development of the asthma control test☆A survey for assessing asthma control.
58 *Journal of Allergy and Clinical Immunology*. 2004. pp. 59–65.
59 doi:10.1016/j.jaci.2003.09.008
60

- 1
- 2
- 3
- 4
- 5 46. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring
- 6 quality of life in children with asthma. *Qual Life Res.* 1996;5: 35–46.
- 7
- 8 47. Fitzclarence CA, Henry RL. Validation of an asthma knowledge questionnaire. *J*
- 9 *Paediatr Child Health.* 1990;26: 200–204.
- 10
- 11 48. Praena Crespo M, Lora Espinosa A, Aquino Llinares N, Sánchez Sánchez AM,
- 12 Jiménez Cortés A. [The Spanish version of the Newcastle Asthma Knowledge
- 13 Questionnaire for parents of children with asthma (NAKQ). Transcultural
- 14 adaptation and reliability analysis]. *An Pediatr.* 2009;70: 209–217.
- 15
- 16 49. Franco R, Nascimento HF, Cruz AA, Santos AC, Souza-Machado C, Ponte EV, et al.
- 17 The economic impact of severe asthma to low-income families. *Allergy.* 2009;64:
- 18 478–483.
- 19
- 20 50. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic
- 21 reference values for spirometry for the 3-95-yr age range: the global lung
- 22 function 2012 equations. *Eur Respir J.* 2012;40: 1324–1343.
- 23
- 24 51. Association for Respiratory Technology & Physiology. ARTP COVID-19 GROUP:
- 25 Practical guidance for increasing Lung Function and Sleep activity during COVID-
- 26 19 Endemic Phase. Aug 2020 [cited 25 Jan 2021]. Available:
- 27 [https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVI](https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVID_Practical_Innovations_Vers1.2_final.pdf)
- 28 [D_Practical_Innovations_Vers1.2_final.pdf](https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVID_Practical_Innovations_Vers1.2_final.pdf)
- 29
- 30 52. PCRS. Position Statement Diagnostic work up of the patient presenting with
- 31 respiratory symptoms during the COVID-19 pandemic. In: The Primary Care
- 32 Respiratory Society [Internet]. 17 Sep 2020 [cited 25 Jan 2021]. Available:
- 33 [https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-](https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-asthma-COPD-during-Covid-19-v2-17-September-2020.pdf)
- 34 [asthma-COPD-during-Covid-19-v2-17-September-2020.pdf](https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-asthma-COPD-during-Covid-19-v2-17-September-2020.pdf)
- 35
- 36 53. Coronavirus & the 2nd Generation NObreath - Update. In: NObreath [Internet].
- 37 [cited 25 Jan 2021]. Available: [https://www.nobreathfeno.com/coronavirus-and-](https://www.nobreathfeno.com/coronavirus-and-the-2nd-generation-nobreath-update/)
- 38 [the-2nd-generation-nobreath-update/](https://www.nobreathfeno.com/coronavirus-and-the-2nd-generation-nobreath-update/)
- 39
- 40 54. Guevara Á, Vivero S, Nipaz V, Guaraca V, Coloma J. A Low-Cost SARS-CoV-2 rRBD
- 41 ELISA to Detect Serostatus in Ecuadorian Population with COVID-19. *Am J Trop*
- 42 *Med Hyg.* 2021. doi:10.4269/ajtmh.20-1420
- 43
- 44 55. AAAAI. Spirometry during COVID-19. In: American Academy of Allergy, Asthma &
- 45 Immunology [Internet]. 23 Apr 2020 [cited 25 Jan 2021]. Available:
- 46 <https://www.aaaai.org/ask-the-expert/spirometry>
- 47
- 48 56. Stanojevic S, Beaucage F, Comondore V, Faughnan M, Kovesi T, McCoy C, et al.
- 49 Resumption of pulmonary function testing during the post-peak phase of the
- 50 COVID-19 pandemic. *Canadian Journal of Respiratory, Critical Care, and Sleep*
- 51 *Medicine.* 2020. pp. 156–159. doi:10.1080/24745332.2020.1796211
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 57. McGowan A, Sylvester K, Burgos F, Boros P, de Jongh F, Kendrick A, et al.
- 5 Recommendation from ERS Group 9.1 (Respiratory function
- 6 technologists/Scientists) Lung function testing during COVID-19 pandemic and
- 7 beyond. ; 2020 [accessed 2020 Aug 31]. In: European Respiratory Society
- 8 [Internet]. [cited 18 Jul 2020]. Available:
- 9 <https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h>
- 10
- 11
- 12 58. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in
- 13 logistic and Cox regression. *Am J Epidemiol.* 2007;165: 710–718.
- 14
- 15 59. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of
- 16 the number of events per variable in logistic regression analysis. *J Clin Epidemiol.*
- 17 1996;49: 1373–1379.
- 18
- 19 60. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per
- 20 independent variable in proportional hazards analysis. I. Background, goals, and
- 21 general strategy. *J Clin Epidemiol.* 1995;48: 1495–1501.
- 22
- 23 61. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per
- 24 independent variable in proportional hazards regression analysis. II. Accuracy
- 25 and precision of regression estimates. *J Clin Epidemiol.* 1995;48: 1503–1510.
- 26
- 27 62. White IR, Royston P, Wood AM. Multiple imputation using chained equations:
- 28 Issues and guidance for practice. *Stat Med.* 2011;30: 377–399.
- 29
- 30 63. White IR, Royston P. Imputing missing covariate values for the Cox model. *Stat*
- 31 *Med.* 2009;28: 1982–1998.
- 32
- 33 64. Royston P, Altman DG. External validation of a Cox prognostic model: principles
- 34 and methods. *BMC Med Res Methodol.* 2013;13: 33.
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44

45 **Author statement:** Study design – PJC, AAC, NR, MB, MP, CA-G; study conduct – DM,

46 SM-B, AO, MEC, CR, AM, KA, AR, CF; manuscript drafting – PJC, DM, SM-B; statistical

47 analysis plan – ICS; manuscript editing and review – all authors.

48

49

50

51 **Funding:** This work is based on the Asthma Attacks Causes and Prevention Study in

52 Urban Latin America which is funded by the National Institute of Health Research

53 [NIHR] under the Global Health Research Programme [grant 17/63/62]. Additional

54

55

56

57

58

59

60

1
2
3
4 financial support was provided by the Corporación Ecuatoriana para el Desarrollo de
5 la Investigación y la Academia CEDIA [N° CEPRA-XV-2021-03].
6
7
8
9

10 **Competing Interests statement:** The authors declare no competing interests.
11
12

13 **Patient and public involvement statement:** There was no patient or public
14 involvement in the design or conduct of this study. Results of tests are being provided
15 at the time of testing and the study population is being informed of study results
16 through periodic leaflets, a website, social media texts and videos, and study group
17 online meetings.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

152x107mm (144 x 144 DPI)




Figure 2

408x217mm (160 x 160 DPI)

BMJ Open

A prospective study of factors associated with asthma attack recurrence (ATTACK) in children from three Ecuadorian cities during COVID-19: a study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056295.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Apr-2022
Complete List of Authors:	Morillo, Diana; Universidad Internacional del Ecuador Mena-Bucheli, Santiago; Universidad Internacional del Ecuador Ochoa, Angélica; Universidad de Cuenca Chico, Martha E; Universidad Internacional del Ecuador Rodas, Claudia; Universidad de Azuay Maldonado, Augusto; Universidad San Francisco de Quito; Hospital General Docente Calderón Arteaga, Karen; Hospital Verdi Cevallos Balda Alchundia, Jessica; Hospital de Especialidades Portoviejo Solorzano, Karla; Hospital de Especialidades Portoviejo Rodriguez, Alejandro ; Universidad Internacional del Ecuador Figueiredo, Camila; Universidade Federal da Bahia Ardura-Garcia, Cristina; University of Bern Bachmann, Max; Univeristy of East Anglia, Norwich Medical School, University of East Anglia Perkin, Michael; St George's, Population Health Research Institute Chis Ster, Irina; St. George's University of London; St George's University of London Cruz, Alvaro; Universidade Federal da Bahia Romero, Natalia; Universidad Internacional del Ecuador, Quito, School of Medicine; Grups de Recerca d'America i Africa Llatines, GRAAL Cooper, Philip; Universidad Internacional del Ecuador; St George's University of London
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Global health, Epidemiology, Public health
Keywords:	Asthma < THORACIC MEDICINE, COVID-19, Epidemiology < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

Title: A prospective study of factors associated with asthma attack recurrence (ATTACK) in children from three Ecuadorian cities during COVID-19: a study protocol

Authors

Diana Morillo¹, Santiago Mena-Bucheli¹, Angélica Ochoa², Martha E Chico¹, Claudia Rodas³, Augusto Maldonado^{4,5}, Karen Arteaga⁶, Jessica Alchundia⁷, Karla Solorzano⁷, Alejandro Rodriguez¹, Camila Figueiredo⁸, Cristina Ardura-Garcia⁹, Max Bachmann¹⁰, Michael Perkin¹¹, Irina Chis Ster¹¹, Alvaro A Cruz^{8, 12}, *Natalia Romero^{1,13}, *Philip J Cooper^{1,11}

Affiliations

¹ Universidad Internacional del Ecuador, Quito, Ecuador.

² Universidad de Cuenca, Cuenca, Ecuador.

³ Universidad de Azuay, Cuenca, Ecuador

⁴ Universidad San Francisco de Quito, Quito, Ecuador

⁵ Hospital General Docente Calderón, Quito, Ecuador

⁶ Hospital Verdi Cevallos Balda, Portoviejo, Ecuador

⁷ Hospital de Especialidades, Portoviejo, Ecuador

⁸ Universidade Federal da Bahia, Salvador, Brazil

⁹ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

¹⁰ University of East Anglia, Norwich, UK.

¹¹ St George's University of London, London, UK.

¹² ProAR-Center of Excellence in Asthma, Salvador, Brazil

¹³ Grups de Recerca d'Amèrica i Àfrica Llatines GRAAL, Barcelona, Spain

*Contributed equally

Correspondence

Philip J. Cooper, Escuela de Medicina, Universidad Internacional del Ecuador, Av. Jorge Fernández y Av. Simon Bolivar, Quito, Ecuador.

Email: pcooper@sgul.ac.uk

Word count
Abstract: 299
Text: 4,372

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- Asthma attacks are a growing cause of morbidity in children and burden on health systems in low and middle-income countries, and there is limited information on factors associated with asthma attacks in poor urban settings in Latin America.
- This protocol describes a study designed to investigate risk factors associated with recurrence of asthma attacks in children and adolescents living in marginalized settings in three Ecuadorian cities.
- This study is recruiting children and adolescents with uncontrolled asthma symptoms and asthma attacks and following them prospectively for 6 to 12 months to identify factors associated with recurrence of attacks in the context of the COVID-19 pandemic.
- The COVID-19 pandemic has had a major impact on health seeking behaviours while mitigation strategies to control transmission of the novel coronavirus, SARS-CoV-2, have resulted in marked declines in the circulation of respiratory viruses that are considered to underlie a high proportion of asthma attacks. Such factors may interfere with recruitment and follow-up of study participants.

Abstract

Introduction: Asthma is a growing health problem in children in marginalized urban settings in low and middle-income countries. Asthma attacks are an important cause of emergency care attendance and long-term morbidity. We designed a prospective study, the Asthma Attacks study (ATTACK), to identify factors associated with recurrence of asthma attacks (or exacerbations) among children and adolescents attending emergency care in three Ecuadorian cities.

Methods and analysis: Prospective cohort study designed to identify risk factors associated with recurrence of asthma attacks in 450 children and adolescents aged 5 to 17 years attending emergency care in public hospitals in three Ecuadorian cities (Quito, Cuenca, and Portoviejo). The primary outcome will be rate of asthma attack recurrence during up to 12 months of follow-up. Data are being collected at baseline and during follow-up by questionnaire: sociodemographic data, asthma history and management (baseline only); recurrence of asthma symptoms and attacks (monthly); economic costs of asthma to family; Asthma Control Test; Pediatric Asthma Quality of life Questionnaire; and Newcastle Asthma Knowledge Questionnaire (baseline only). In addition, the following are being measured at baseline and during follow-up: lung function and reversibility by spirometry before and after salbutamol; fractional exhaled nitric oxide (FeNO); and presence of IgG antibodies to SARS-CoV-2 in blood. Recruitment started in 2019 but because of severe disruption to emergency services caused by the COVID-19 pandemic, eligibility criteria were modified to include asthmatic children with uncontrolled symptoms and registered with collaborating hospitals. Data will be analysed using logistic regression and survival analyses.

Ethics and dissemination: Ethical approval was obtained from the Hospital General Docente de Calderon (CEISH-HGDC 2019-001) and Ecuadorian Ministry of Public Health (MSP-CGDES-2021-0041-O N° 096-2021). The study results will be disseminated through presentations at conferences and to key stakeholder groups including policy makers, postgraduate theses, peer-review publications, and a study website.

Introduction

Asthma is the most common chronic disease of childhood and is estimated to affect more than 350 million people worldwide [1]. Although initially described as a disease of high-income countries (HICs) such as the United Kingdom, international comparisons using standardized methodologies have shown a similar or greater prevalence among children in urban centres in Latin America as observed in HICs [2]. There is evidence that the prevalence of asthma has increased in low- and middle-income countries (LMICs) over recent decades [2].

Asthma attacks or exacerbations are frequent in children and are a common cause of hospitalization [3], most frequently associated with respiratory viral infections [4], but also with exposures to allergens [5] and air pollution [6] among individuals with an underlying genetic susceptibility [7]. Asthma is an underdiagnosed disease because of lack of specialized personnel and resources to evaluate lung function. Further, limited access to specialized care and treatment [8], accompanied by poor treatment adherence [9,10] are important contributing factors to inadequate disease control and attacks, especially in underprivileged populations. In such settings, asthma patients with poor control of their daily symptoms often rely on emergency room care for management of their symptoms [11], resulting in high economic costs to health systems and patients' families [8,12].

To understand better factors contributing to the risk of asthma attacks, it is important identify those factors contributing to suboptimal management which can be improved through better health care [13]. Several studies have investigated potential predictors of recurrence of asthma attacks among children attending emergency services. Factors identified as important included a history of previous emergency attendances for acute asthma attacks, younger age [13–15], ethnicity of African descent [16,17], and low socioeconomic status [13,18]. These studies were conducted almost exclusively in North America and frequently included adult Hispanic populations living there. There are relatively few such studies done in LMICs [13,16,18].

1
2
3
4 The Asthma Attacks Study (ATTACK) aims to identify factors related to recurrence of
5 asthma attacks in Ecuadorian children attending emergency care in three Ecuadorian
6 cities. Recruitment into the study started in March 2019 but was interrupted by the
7 COVID-19 pandemic that had a major impact on use of and access to emergency care
8 [19]. In consequence, the original protocol was modified to allow continued
9 recruitment and measure the impact of the COVID-19 pandemic and exposures to
10 SARS-CoV-2 on asthma attacks in children and adolescents.
11
12
13
14
15
16
17
18

19 *What is known about factors related to asthma attacks and impact of COVID-19*
20 *pandemic?*
21

22 Severe asthma in children is associated with loss of lung function [20], as well as with
23 high costs of medical and family care [2]. In Latin America, asthma has been described
24 as a major public health problem because of a high prevalence and significant
25 associated morbidity and mortality [21]. Asthma control among children in Latin
26 America has been reported to be among the worse worldwide [22–25]. The Latin
27 America Asthma Insights and Management study reported adequate asthma control
28 in less than 20% of asthmatic children in Argentina, Brazil, Mexico, Venezuela, and
29 Puerto Rico [22]. A case-control study of asthmatic children with an acute attack
30 attending an Emergency Room (ER) in coastal Ecuador showed that, over the previous
31 12 months, only 20% of children had visited a doctor in the past year for a routine visit,
32 86% had attended an emergency room at least once prior, and none were receiving
33 inhaled corticosteroids despite over half having suffered four or more acute
34 exacerbations [26]. A previous prospective study of children with asthma attacks in
35 coastal Ecuador showed a recurrence rate of 46% within 6 months [13].
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Asthma attacks represent an acute or subacute increase in respiratory symptoms [25]
51 and severe attacks - defined as requiring ER or hospital care and treatment with
52 systemic corticosteroids for at least 3 days - are associated with loss of lung function
53 [20] and high economic costs to the patient's family and health care system [7], as well
54 as absenteeism in work and school.
55
56
57
58
59
60

1
2
3
4 Asthma attacks may be prevented either by avoiding previously identified triggers or
5
6 by appropriate preventive treatment. Patients using inhaled corticosteroids (ICS) were
7
8 3 times more likely to have well-controlled asthma [22], a reduction in symptoms
9
10 independent of frequency, and better lung function [1]. In Brazil, preventive strategies
11
12 have been successfully implemented through asthma control programs such as Pro-AR
13
14 in Salvador de Bahía to reduce future risk in asthmatic patients from less privileged
15
16 backgrounds, through the provision of ICS [27]. There has been a shift to using ICS more
17
18 widely for control of asthma, for example, through the provision of combination
19
20 inhalers including both ICS and a beta₂ agonist for moderate to severe asthma [28].
21
22 More recent evidence indicate that the use of ICS may be beneficial even for asthmatic
23
24 children with mild disease that accounts for 30-40% of severe attacks [29]. Treatment
25
26 recommendations for children and adolescents with mild disease are now shifting to
27
28 use of ICS (plus long-acting beta-agonists in combination inhalers) as required [30,31].
29
30 Despite such initiatives, access to ICS in many LMIC settings is limited within health
31
32 care systems because of cost and a failure to recognize the public health impact of
33
34 childhood asthma. In such settings, children with asthma symptoms frequently over-
35
36 rely on ER care for the acute control of their symptoms in the absence of adequate
37
38 provision of specialized care for their long-term management [26,32].

39
40 Soon after the emergence of the novel coronavirus, SARS-CoV-2, in humans and its
41
42 spread into a global pandemic, the question was raised as to whether this novel viral
43
44 infection might alter the risk of asthma symptoms because of deficient antiviral
45
46 immune responses and the tendency to increase exacerbations during infections with
47
48 other respiratory viruses [33]. To date, evidence from studies of asthmatic children and
49
50 adults do not indicate an increased risk [34,35]. Characteristics of asthmatic airways
51
52 among those with T2-linked phenotypes may reduce the expression of the cellular
53
54 receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), in the airways [36].
55
56 It has been suggested that the use of ICS among asthmatics may reduce risk of severe
57
58 COVID-19 by suppressing inflammation and enhancing antiviral defenses [37],
59
60 although the evidence remains unclear [38]. There are limited data from pediatric
populations [38]. The COVID-19 pandemic has resulted in marked reductions in

1
2
3
4 hospital visits including to emergency rooms (Figure 1), reduced attack rates, and
5 better lung function among children with asthma [19,39], which are likely
6 consequences of mitigation measures to reduce transmission of SARS-CoV-2 (such as
7 lockdowns, face masks, and social distancing) that have resulted also in the reduced
8 transmission of other respiratory viruses [4,6,10,39]. Treatment adherence may have
9 improved also because of better parental supervision of asthma medications [40].
10 There are limited data on the impact of exposure to SARS-CoV-2 on asthma attacks and
11 uncontrolled symptoms and the impact of the collateral effects of the COVID-19
12 pandemic including reduced access to health services and medications and effects of
13 COVID-19 mitigation efforts in resource-poor LMIC settings.
14
15
16
17
18
19
20
21
22
23

24 **Figure 1: Impact of the COVID-19 pandemic in the 3 study centres in Quito, Portoviejo**
25 **and Cuenca, Ecuador, on recruitment rates into the study and number of potentially**
26 **eligible subjects identified in collaborating emergency rooms. Red bars show**
27 **numbers recruited as a proportion (%) of those eligible (blue bars) prior to a legally**
28 **enforced national lockdown on 16th March 2020.**
29
30
31
32
33

34 **Methods and analysis**

35 *The Asthma Attack study*

36
37 A prospective multi-center study is being done in children aged 5 to 17 years in low-
38 income settings in three Ecuadorian cities (Quito, Cuenca, and Portoviejo) to study
39 factors associated with acute asthma attacks. Because of the impact of the COVID-19
40 pandemic on risk of asthma attacks and health care access, the study was divided into
41 2 phases of recruitment and follow-up: 1) Phase I (or pre-COVID-19 from May 2019 to
42 March 2020) evaluated risk factors associated with recurrence of acute asthma attacks
43 among children and adolescents attending emergency rooms of public hospitals in low-
44 income settings in the three cities; and 2) Phase II (or peri-COVID-19 from March 2021
45 to June 2022) is evaluating risk factors associated with attacks among children and
46 adolescents with asthma and current symptoms who have previously attended
47 specialist care at public hospitals in Cuenca and Portoviejo. Phase II is also evaluating
48 the effects of exposures to SARS-CoV-2 on asthma attacks and symptoms. In addition,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 both study phases are evaluating the impact of asthma symptoms and adequate
5 control of asthma on the quality of life and economic costs for the family of children
6 and adolescents with asthma. The objectives of Phases I and II are detailed in Table 1.
7
8 Qualitative studies of health worker's perspectives on asthma care coordination
9 between primary and specialized health care are being done also as described
10 elsewhere [41].
11
12
13
14
15
16

17 *Study design and setting*

18 This is a multi-center prospective study conducted in three Ecuadorian cities (Quito,
19 Cuenca, and Portoviejo). Quito, the capital, and Cuenca, the third largest city, are
20 located in the Andean highlands (altitude >2,500m) where the annual average
21 temperature is ~16°C, while Portoviejo is in the coastal region (at sea level) with an
22 annual average temperature of ~25 °C [42]. According to the 2010 census, the
23 populations of the three cities are: Quito >2 million, Cuenca 0.5 million, and Portoviejo
24 0.28 million inhabitants. Ecuador is an upper-middle-income-country with a per capita
25 income of \$6,080 in 2019. The health system in Ecuador includes public and private
26 provision. Public institutions offer universal health coverage that is stratified into
27 different levels of care from primary to tertiary services [43]. Social security institutions
28 offer health services to affiliated salaried workers and their families. The private sector
29 includes for-profit entities (hospitals, clinics, dispensaries, doctor's offices, pharmacies,
30 and prepaid health insurance companies) which are generally located in the main cities
31 [44].
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 *Study centers*

47 The study was initially based in the tertiary care hospitals in each of the three cities
48 (Hospital Docente General de Calderon, Quito; Hospital Vicente Corral Moscoso,
49 Cuenca; and Hospital Verdi Cevallos Balda, Portoviejo).
50
51
52
53
54
55
56
57
58
59
60

PHASE	OBJECTIVES	HOW OBJECTIVE WILL BE ACHIEVED	STATISTICAL OUTCOME	STATISTICAL METHODS	STATISTICAL INFERENCE
1	PRIMARY:				
	Risk factors associated with asthma attacks recurrence requiring an emergency visit during follow-up	Monthly follow-up and recording of events	Binary: Yes/No indicating at least one individual recurrence	Logistic regression	OR and 95% CIs; Predictive model for recurrence, ROC and AUC
	SECONDARY:				
	1. Risk factors associated with time to first asthma attack recurrence	Monthly follow-up and recording of events	Binary: Yes/No indicating the first recurrence and/or time to the first event	Survival analyses modelling time to first event	HR and 95% CIs; Survival models – proportional hazard (semi-parametric Cox or parametric Weibull) or accelerated time failure depending on data
	2. Risk factors associated with monthly asthma attack recurrence	Monthly follow-up and recording of events	Longitudinal binary outcomes indicating events and times	Longitudinal binary outcome	OR; HR and 95 %CIs; Longitudinal binary models (GEE)
	3. Evaluate impact of asthma recurrence and control on quality of life and economic costs for patient’s families.	Monthly follow-up and recording of events and questionnaire on asthma control (0, 6, & 12 months) and quality of life and economic costs at 6 & 12 months.	Longitudinal continuous outcomes indicating scores for quality of life and economic costs	Longitudinal continuous data outcomes and time-varying covariates	Multiple events per individual - frailty survival analysis Longitudinal continuous data analysis with time varying binary covariates indicating presence of recurrent event
2	PRIMARY:				
	Risk factors associated with asthma attacks recurrence requiring an emergency visit during follow-up	Monthly follow-up and recording of events	Binary: Yes/No indicating at least one individual recurrence during follow-up	Logistic regression	OR and 95% CIs; Predictive model, ROC, AUC
	SECONDARY:				
	1. Risk factors associated with time to first asthma attack recurrence	Monthly follow-up and recording of events	Binary: Yes/No indicating the first recurrence and/or time to first event	Survival type analyses modelling time to first event	HR and 95% CIs; Survival models – proportional hazard (semi-parametric Cox or parametric Weibull) or accelerated time failure depending on data
	2. Risk factors associated with monthly asthma attack recurrence	Monthly follow-up and recording of events	Longitudinal binary outcomes indicating events and times	Longitudinal binary outcome	OR; HR and 95% CIs; Longitudinal binary models (GEE estimation)
	3. Evaluate impact of asthma recurrence and control on quality of life and economic costs for patient’s families.	Monthly follow-up and recording of events and questionnaire on asthma control (0, 6, & 12 months) and quality of life and economic costs at 6 & 12 months.	Longitudinal continuous outcomes indicating scores for quality of life and economic costs	Longitudinal continuous outcomes and time-varying covariates	Multiple events per individual - frailty survival analysis OR and 95% CIs; Longitudinal continuous data analysis with time varying binary covariates indicating presence of recurrent event
	4. Effects of seropositivity to SARS-CoV-2 on risk of any asthma attack recurrence and number of events	Serology for SARS-CoV-2 at 0 & 6 months	Longitudinal binary outcomes indicating events and times	Longitudinal binary outcome and time-varying covariates	Longitudinal binary analysis with time varying binary indicating SARS-CoV-2 serology. Both population average (PA) and subject-specific (SS) models to be considered given time-varying nature of the SARS-CoV-2 variable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table 1. Study objectives for Phases I and II, how each objective will be achieved, and statistical analysis for each objective

OR - ODDS RATIOS; 95% CIs – 95% confidence intervals; HR – Hazard ratios; ROC- Receiving operator characteristic; AUC - area under the curve; GEE – generalized estimating equations

1
2
3
4 *Recruitment - Phase I (pre-COVID-19; May 2019 to March 2020)*

5
6 Children and adolescents aged 5–17 years were recruited either while attending
7 emergency rooms (ERs) with an asthma attack or through daily registries and contact
8 telephone numbers of patients attending the ERs with an asthma attack. From May
9 2019, eligible patients (Table 2) were provided with a study information sheet on
10 discharge and their parents were contacted to arrange an interview at a hospital
11 consulting room 10–14 days later when they were recruited into the study after
12 providing informed written parental consent and minor assent (8 years and older).
13
14
15
16
17
18
19

20
21 *Recruitment – Phase II (peri-COVID-19; March 2021 to March 2022)*

22 The COVID-19 pandemic had a dramatic impact on our ability to recruit children with
23 asthma attacks in the three study hospitals that resulted in the suspension of
24 recruitment in March 2020. This was owing to the reassignment of all 3 hospitals to
25 COVID-19-only activities for prolonged periods and the imposition of a legally enforced
26 lockdown nationally. Figure 2 shows the number of potentially eligible children
27 identified in the 3 study hospitals by month in the period prior to COVID-19 and during
28 the pandemic. There was as a marked reduction in eligible children attending the ERs
29 immediately following the imposition of lockdown on 16th March 2020 and in the
30 following 8 months. In the period following the initial lockdown and other mitigation
31 strategies to reduce transmission of SARS-CoV-2, within the sample of asthmatic
32 children recruited into Phase I of the study, there was evidence of dramatic reduction
33 in health service attendance rather than changes in the incidence of attacks [19]. To
34 allow continued recruitment, a second phase (Phase II) of the study was started with
35 eligibility criteria modified to include children and adolescents aged 5–17 years
36 registered as having asthma in patient registries at the study hospitals in Cuenca and
37 Portoviejo (Quito was not included in Phase II because of logistic issues in that specific
38 setting). The child's parent was contacted by telephone and asked about the child's
39 current asthma symptoms. Children with current symptoms were considered eligible.
40 Eligibility criteria for Phase I and II are shown in Table 2.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Eligibility criteria for entry into Phase I and Phase II of study

Characteristic	Phase I	Phase II
Setting/study population	Public hospital ERs in Quito, Cuenca, and Portoviejo	Public hospital registry of patients with asthma in Cuenca and Portoviejo
Inclusion criteria	<ol style="list-style-type: none"> 1. Aged 5-17 years 2. Acute asthma attack attending ERs at public hospitals 3. Living within 12 km of public hospital 4. Informed written consent from parents 5. Minor assent from children ≥ 8 years 	<ol style="list-style-type: none"> 1. Aged 5-17 years 2. Wheeze within the last 6 months 3. Living within 12 km of public hospital 4. Informed written consent from parents 5. Minor assent from children ≥ 8 years
Exclusion criteria	<ol style="list-style-type: none"> 1. Other chronic disease 2. Living >12 km from public hospital 	<ol style="list-style-type: none"> 1. Other chronic disease 2. Living >12 km from public hospital

Data collection

A study manager supervised day-to-day activities of a dedicated teams (physician and nurse) of trained study personnel based in each of the public hospitals. Each participant was followed up for 12 months in Phase I and at least 6 months in Phase II. Standardized procedures were used throughout (Figure 2). Subjects were evaluated at monthly intervals using face-to-face and telemonitoring for follow-up. Both phases include face-to-face evaluations (evaluations at baseline, 2, 4, 6, 9, and 12 months in Phase I; baseline, 6, and 12 months in Phase II). Between March 2020 and March 2021, all face-to-face evaluations in Phase I were changed to telemonitoring apart from the final evaluation at 12 months which remained face-to-face, where possible. Final face-to-face evaluations were done in March-April 2021 on participants who had completed 12 months of follow-up between June 2019 and February 2020. The site of face-to-face evaluations was changed to either a clinic or home visit depending on the preference of the child's parents. Study procedures were the same in both phases of the study (Figure 2) with the following exceptions: 1) procedures requiring face-to-face evaluations at 6 and 12 months in Phase I (C-ACT, and PAQLQ) were dropped in Phase

1
2
3
4 II and the remaining instruments were administered by telemonitoring; 2) blood
5 samples (baseline, 6, and 12 months) are being collected from those recruited into
6 Phase II of the study for measurement of anti-SARS-CoV-2 IgG antibodies; and 3)
7 measurement of lung function and fractional exhaled nitric oxide was suspended from
8 March 2020 because of risks from potentially hazardous infectious aerosols until a time
9 when this procedure can be done safely. Medications (inhaled salbutamol and
10 fluticasone) were provided free of charge to participants when prescribed by a hospital
11 physician and there was no medication in the hospital pharmacy. The study team
12 ensured adequate inhaler technique during face-to-face clinic or home visits. Study
13 personnel did not interfere with treatment indications of hospital staff.
14
15
16
17
18
19
20
21
22
23

24 **Figure 2. Study procedures during baseline evaluation and follow-up in Phases I (A)**
25 **and II (B) of study.**

26 **BaselineQ – General questionnaire based on Phase II of the International Study of**
27 **Asthma and Allergies in Childhood; AFCQ- Asthma Family Costs Questionnaire; NAKQ**
28 **– Newcastle Asthma Knowledge Questionnaire; ACT – Asthma Control Questionnaire**
29 **(>11 years); C-ACT – Child Asthma Control Questionnaire (>=12 years); ARQ – Asthma**
30 **Recurrence Questionnaire; FeNO – fractional exhaled nitric oxide. Follow-up in Phase**
31 **I was for 12 months and in Phase II for a minimum of 6 months.**
32
33
34
35
36
37
38
39
40
41
42

43 *Questionnaires at baseline and follow-up*

44 The following questionnaires were used as indicated in Figure 2; i) asthma
45 questionnaire to collect information on history of asthma symptoms, treatment and
46 management, and potential risk factors for asthma attacks. This questionnaire has
47 been previously adapted from ISAAC Phase II and extensively field-tested for children
48 and adolescents with asthma [13,26]; ii) Asthma Recurrence Questionnaire (ARQ) -
49 questionnaire to monitor recurrence of asthma symptoms and monitor treatment
50 during follow-up [13], and including symptoms and diagnosis of COVID-19 in Phase II;
51 iii) Childhood Asthma Control Test (C-ACT) [45], completed by the child and parent for
52 children aged <12 years or the ACT [46] for those aged ≥ 12 years; iv) Pediatric Asthma
53
54
55
56
57
58
59
60

Quality of Life Questionnaire (PAQLQ) [47]; v) Newcastle Asthma Knowledge Questionnaire (NAKQ) [48,49] validated in a Spanish-speaking populations; and vi) Asthma Family Cost Questionnaire (AFCQ) [50]. Data collection is summarized in Table 3.

Table 3 Data collection at baseline and during follow-up in Phases I and II of study

Data collected	Baseline	Month 6	Month 12	Monthly
Asthma diagnosis	I/II			
History of asthma symptoms	I/II			
Current asthma symptoms	I/II	I/II	I/II	I/II
ER visits/ hospitalizations	I/II	I/II	I/II	I/II
Asthma medications	I/II	I/II	I/II	I/II
Asthma control (C-ACT/ACT)	I/II	(I)/II	(I)/II	
Asthma quality of life (PAQLQ)	I/II	(I)/II	(I)/II	
Asthma knowledge (NAKQ)	I			
Lung function	I/(II)	(I)/II	(I)	
Reversibility	I/(II)	(I)/II	(I)	
FeNO	I/II	(I)/II	(I)/II	
Anti-SARS-CoV-2 IgG antibodies	II	II	II	
COVID-19 symptoms or diagnosis	II	II	II	II

FeNO – fractional exhaled nitric oxide. (I) – data collection where possible

Lung function test and Fractional Exhaled Nitric Oxide (FeNO)

1
2
3
4 Lung function testing is being done according to American Thoracic Society (ATS)
5 criteria using a portable ultrasonic spirometer (EasyOne® device, ndd Medical
6 Technologies). Global Lung Function Initiative (GLI-2012) reference values will be used
7
8 to calculate z-scores depending on age, sex, height, and ethnicity [51]. Lung function is
9
10 being measured before and before and after 200 ug salbutamol administered through
11
12 a spacer with a positive test for airways reactivity defined as an increase in FEV₁ of
13
14 $\geq 12\%$. Fractional exhaled nitric oxide (FeNO) is being measured in parts per billion
15
16 using NObreath (Bedfont Scientific, UK). As a consequence of lockdown and mitigation
17
18 strategies to prevent transmission of SARS-CoV-2, measurement of lung function and
19
20 FeNO was suspended in March 2020. FeNO measurement, a low effort procedure that
21
22 carries a minimal risk of generating aerosols [52,53], was resumed in March 2021 for
23
24 12-month evaluations in Phase I and baseline evaluations in Phase II. FeNO is being
25
26 done following the recommendations of the manufacturer to minimize potential risks
27
28 [54]. Spirometry, which often induces cough, will be resumed, only if the procedure
29
30 can be done without risk to staff, patients, and their families.
31
32

33 *Blood samples*

34
35 Blood sample are being taken at baseline, 6 and 12 months in Phase II. Blood is drawn
36
37 from an antecubital vein into a 4 mL plastic tube containing EDTA as anticoagulant
38
39 (Vacutainer, BD). After centrifugation, plasma is stored at -20C until analysis. Levels of
40
41 IgG specific for SARS-CoV-2 are being measured using a validated enzyme linked
42
43 immunosorbent assay [55].
44
45

46 *Biosafety precautions relating to the COVID-19 pandemic*

47
48 Personnel gathering data during face-to-face visits have been trained to use
49
50 appropriate personal protective equipment according to international guidelines
51
52 [56–58]. Immediately prior to a home or clinic visit, the child’s carer is telephoned
53
54 about potential symptoms or a COVID-19 diagnosis among family members or close
55
56 contacts – if any symptoms are reported the visit is rescheduled after 2 weeks.
57
58

59 *Sample size considerations*

60

1
2
3
4 A sample size of 450 patients was proposed for Phase I, based on a binary outcome
5 variable of any recurrence of an asthma attack within 12 months or so. We used an
6 estimated recurrence risk of about 50% during 6 months follow-up from a similar
7 population in Ecuador [13]. The study should collect between 10 and 16 outcome
8 events per each potential explanatory variable for robust results (i.e. for at least 80%
9 power, equivalent to a type 2 error of less than 20% as proven by simulation studies).
10 Assuming 10 explanatory variables are considered, in the worst-case scenario,
11 $10 \times 16 = 160$ such events would be required for the upper limit of 16 events for each
12 explanatory variable. Given a 50% risk of recurrence, a minimum of $160 \times 2 = 320$
13 subjects will be needed. Allowing for 20% attrition/loss during follow up given the
14 longitudinal nature of the study, we needed approximately 400 patients which we set
15 more conservatively at 450 [59–62]. However, we do not expect a multivariable model
16 to exceed 10 predictors. There is the possibility of differences between populations
17 recruited during the 2 phases of the study. If this is not the case, an indicator variable
18 which annotates the two phases will be added to the set of predictors and 450 patients
19 would still allow at least 80% power under the conditions described. For example, if 11
20 predictors are considered, 352 patients would be required or a total of 440 allowing
21 for 20% attrition. If there are substantial differences between subjects recruited in the
22 two phases, analyses will consider up to 10 events per explanatory variable requiring
23 100 events per phase among 200 participants followed-up or 250 recruited (allowing
24 for 20% attrition). The latter scenario will require recruitment of a total of 500 during
25 the two phases, a target that we are confident we can achieve.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 The definition of an asthma attack in both phases of the study is an episode of acute
47 wheezing requiring an unscheduled visit to a health professional (including visits to
48 ERs) and which is controlled by β_2 -agonist bronchodilator treatment. The original
49 definition for an asthma attack in Phase I that included ER attendance had to be
50 modified in the light of changes in health seeking behaviour caused by the COVID-19
51 pandemic and fear of contagion in hospitals and other acute health facilities [19].
52 Potential explanatory variables include age, gender, ethnicity, socioeconomic status,
53 medication use, asthma attacks and use of systemic corticosteroids in year prior to
54
55
56
57
58
59
60

1
2
3
4 recruitment, asthma control test score, and study centre. Given changes to the Phase
5 I protocol, an additional variable (for recruitment from ERs vs. hospital lists) will be
6 considered as an effect modifier. Sub-group analyses of Phase II will include SARS-CoV-
7 2 seropositivity as an explanatory variable. Secondary outcomes will asthma control
8 score and economic costs to the patient's family.
9
10
11
12
13

14 15 *Statistical analyses*

16
17 The statistical models to be used by study objective are summarized in Table 1. The
18 primary outcome will be any asthma attack recurrence during 12 months of follow-up
19 in Phase I and at least 6 months in Phase II. Logistic and linear regression, and survival
20 analyses will be used. For the latter, if no re-attendance related to an asthma attack
21 occurred during the follow-up period, the patient is considered (right) censored. The
22 general assumption for time-to-event (survival analysis) is that the censoring is non-
23 informative, i.e. it is independent of the events (asthma attacks). Under this
24 assumption, the results should not be qualitatively different from those inferred from
25 a logistic regression. Odds ratios and/or hazard ratios and their corresponding p-values
26 and 95% CIs will measure the associations between asthma attack recurrence and
27 explanatory variables, and their statistical significance and uncertainty. The Cox
28 proportional hazard (PH) semi-parametric technique allows no assumption to be made
29 on the baseline hazard; nevertheless, proportionality of the hazards should hold. The
30 latter assumption can be tested on the basis of Shoenfeld residuals after fitting models
31 to the data. If unsatisfactory, alternative parametric models will be considered after
32 understanding the distributional assumptions on the data such that the baseline
33 hazard function is modelled appropriately. After exploring the data as described above,
34 a forward-backward elimination survival analysis would be applied to determine the
35 most parsimonious model for an adjusted multivariable model; that is the model with
36 the least number of predictors yet explaining most of the variability in the data.
37 Penalized-likelihood criteria such as AIC or BIC will be used to choose between non-
38 nested models – nevertheless based on complete observations only.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Hosmer-Lemeshow measure of goodness of fit would be employed for logistic
5 regression models with a p-value of less than 0.05 indicating a poor fit to the data.
6
7 Model validation will be done by splitting the data set into training-testing subsets
8 (logistic regression setting). Cross validation techniques will be used to understand the
9 prediction power of the corresponding logistic regression model using area under the
10 receiver operator curve, prior to propose the model entering the clinical practice with
11 the view of elaborating a prognostic model. In survival setting it is also possible that
12 the precise time of the attacks may be missed but recorded as between two time
13 points. This would fall into interval censored data as an alternative to survival setting
14 in which the precise time of the event is required.
15
16
17
18
19
20
21
22
23

24 Multiple recurrences of asthma attacks within the follow-up period will generate a
25 longitudinal binary outcome, with multiple records for each participant over follow-
26 up. The hierarchical structure of the data requires special inferential techniques which
27 account for the two sources of variability: that of between participants and within
28 participants. Three different modelling approaches will be considered: generalized
29 estimation equation, mixed models, and random effects survival models. The first
30 approach provides population-average estimates, the second provides subject-specific
31 estimates while the third is also known as shared frailty survival model. A frailty is a
32 latent random effect which enters multiplicatively on the hazard function and accounts
33 for the multiple failures setting and/or for the clustered aspect of the data.
34
35
36
37
38
39
40
41
42
43

44 Complete data analyses will be done under missing completely at random
45 assumptions. However, patterns in missing data will be explored and methods to
46 evaluate potential impact of missing data on estimates will be used as appropriate such
47 as multiple imputations using chained equations (MICE) accompanied by a sensitivity
48 analysis to the missing data assumptions [63–65]. Analyses will use STATA (StataCorp.
49 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC) or R (R
50 Core Team (2013)).
51
52
53
54
55
56
57
58

59 Discussion

60

1
2
3
4 The prevalence of childhood asthma has increased in many LMICs over the past 50 or
5 so years where asthma attacks are a growing burden to health systems [2]. There are
6 limited data on determinants of asthma attacks in children and adolescents from LMIC
7 settings [18], and a need for prospective studies to identify risk factors for asthma
8 attacks so that the limited resources available in low-resource settings can be focused
9 on those children most likely to suffer recurrent attacks to reduce morbidity and
10 economic costs to health systems and patients' families. The Asthma ATTACK study
11 aims to identify risk factors associated with asthma attacks among children and
12 adolescents attending emergency rooms in public hospitals in three Ecuadorian cities.
13
14
15
16
17
18
19
20
21

22 This study provides a range of climatic settings in Ecuador from high altitude (Cuenca
23 and Quito) to sea level (Portoviejo). Study activities were interrupted in March 2020
24 by the COVID-19 pandemic resulting in a suspension of recruitment in hospital ERs
25 owing to dramatic changes in access to and use of health facilities. As a consequence,
26 the study protocol was modified to allow re-initiation of recruitment and also the
27 evaluation of the effect of exposures to SARS-CoV-2 on risk of asthma attacks and
28 symptoms in children. The study will help fill an unmet knowledge gap on the effects
29 of SARS-CoV-2 on pediatric asthma, particularly from low-resource LMIC settings [19].
30
31
32
33
34
35
36
37
38

39 *Study limitations*

40 A potential limitation is recruitment of sufficient subjects with an acute asthma attack
41 attending emergency rooms at the three public hospitals and ensuring monthly follow-
42 up in Phase I of the study. The COVID-19 pandemic had a major impact on health
43 seeking behaviours while mitigation strategies to control transmission of the novel
44 coronavirus, SARS-CoV-2, resulted in marked declines in the circulation of respiratory
45 viruses that are considered to cause a high proportion of asthma attacks [66]. A shift
46 to telemonitoring during the COVID-19 pandemic helped ensure almost complete
47 follow-up of those recruited prior to March 2020, although procedures requiring the
48 presence of the patient or that generated potentially hazardous aerosols (e.g.
49 spirometry) had to be suspended. Declines in circulating respiratory viruses [67]
50 because of mitigation strategies against COVID-19 could reduce the number of
51
52
53
54
55
56
57
58
59
60

1
2
3
4 recurrence events and hence the power of the study. Phase II is recruiting known
5 asthmatic children and adolescents with recent asthma symptoms and following them-
6 up for asthma attacks for at least 6 months. The change in criteria should allow
7 sufficient subjects to be recruited given the impact of COVID-19 pandemic on health
8 attendance behaviours, although continuing mitigation measures may reduce
9 recurrence. Follow-up in Phase II is being done through telemonitoring and a few
10 scheduled face-to-face visits either to the study clinic or the participant's home
11 depending on individual preferences. Other potential limitations include missing of
12 events although monthly contacts should minimize these. Significant losses to follow-
13 up that could lead to selection bias are being minimized by regular contacts with
14 caregivers including home visits, and confounding should be reduced by the collection
15 of data on a wide variety of known potential risk factors and confounders including
16 treatments received and adherence to those treatments.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Ethics and dissemination**

31 Ethical approval for Phase I was obtained from the Ethics Committee of the Hospital
32 General Docente de Calderon (CEISH-HGDC 2019-001) and for Phase II from the
33 Ecuadorian Ministry of Public Health COVID-19 Ethics Committee (MSP-CGDES-2021-
34 0041-O N° 096-2021). The study results will be disseminated through presentations at
35 conferences and to key stakeholder groups including policy makers, postgraduate
36 student theses, peer-review publications, and on a study website.
37
38
39
40
41
42
43
44

45 **References**

- 46
47 1. Reddel HK, Busse WW, Pedersen S, Tan WC, Chen Y-Z, Jorup C, et al. Should
48 recommendations about starting inhaled corticosteroid treatment for mild
49 asthma be based on symptom frequency: a post-hoc efficacy analysis of the
50 START study. *Lancet*. 2017;389: 157–166.
51
52
- 53 2. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide
54 trends in the prevalence of asthma symptoms: phase III of the International
55 Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2007;62: 758–766.
56
57
- 58 3. Hasegawa K, Bittner JC, Nonas SA, Stoll SJ, Watase T, Gabriel S, et al. Children
59 and Adults With Frequent Hospitalizations for Asthma Exacerbation, 2012-2013:
60

- 1
2
3
4 A Multicenter Observational Study. *J Allergy Clin Immunol Pract.* 2015;3: 751–
5 8.e1.
6
- 7
8 4. Deschildre A, Pichavant M, Engelmann I, Langlois C, Drumez E, Pouessel G, et al.
9 Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway
10 inflammation and alteration of virus sensors characterize a subgroup of patients.
11 *Respir Res.* 2017;18: 191.
12
- 13
14 5. Murray CS, Foden P, Sumner H, Shepley E, Custovic A, Simpson A. Preventing
15 Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-
16 Impermeable Bedcovers. *Am J Respir Crit Care Med.* 2017;196: 150–158.
17
- 18
19 6. Taquechel K, Diwadkar AR, Sayed S, Dudley JW, Grundmeier RW, Kenyon CC, et
20 al. Pediatric Asthma Health Care Utilization, Viral Testing, and Air Pollution
21 Changes During the COVID-19 Pandemic. *J Allergy Clin Immunol Pract.* 2020;8:
22 3378–3387.e11.
23
- 24
25 7. Bønnelykke K, Sleiman P, Nielsen K, Kreiner-Møller E, Mercader JM, Belgrave D,
26 et al. A genome-wide association study identifies CDHR3 as a susceptibility locus
27 for early childhood asthma with severe exacerbations. *Nat Genet.* 2014;46: 51–
28 55.
29
- 30
31 8. Fischer GB, Sarria EE, Camargos P, Mocelin HT, Soto-Quiroz M, Cruz AA, et al.
32 Childhood asthma in low and middle-income countries: Where are we now?
33 *Paediatr Respir Rev.* 2019;31: 52–57.
34
- 35
36 9. Carroll WD, Wildhaber J, Brand PLP. Parent misperception of control in
37 childhood/adolescent asthma: the Room to Breathe survey. *Eur Respir J.*
38 2012;39: 90–96.
39
- 40
41 10. Vervloet M, van Dijk L, Spreeuwenberg P, Price D, Chisholm A, Van Ganse E, et
42 al. The Relationship Between Real-World Inhaled Corticosteroid Adherence and
43 Asthma Outcomes: A Multilevel Approach. *J Allergy Clin Immunol Pract.* 2020;8:
44 626–634.
45
- 46
47 11. Fleming L. Asthma exacerbation prediction: recent insights. *Curr Opin Allergy
48 Clin Immunol.* 2018;18: 117–123.
49
- 50
51 12. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact.
52 *Asthma Res Pract.* 2017;3: 1.
53
- 54
55 13. Ardura-Garcia C, Arias E, Hurtado P, Bonnett LJ, Sandoval C, Maldonado A, et al.
56 Predictors of severe asthma attack re-attendance in Ecuadorian children: a
57 cohort study. *Eur Respir J.* 2019;54. doi:10.1183/13993003.02419-2018
58
- 59
60 14. Smiley M, Sicignano N, Rush T, Lee R, Allen E. Outcomes of follow-up care after
an emergency department visit among pediatric asthmatics in the military
health system. *J Asthma.* 2016;53: 816–824.

15. Beck AF, Simmons JM, Huang B, Kahn RS. Geomedicine: area-based socioeconomic measures for assessing risk of hospital reutilization among children admitted for asthma. *Am J Public Health*. 2012;102: 2308–2314.
16. Zipkin R, Schragger SM, Nguyen E, Mamey MR, Banuelos I, Wu S. Association between pediatric home management plan of care compliance and asthma readmission. *J Asthma*. 2017;54: 761–767.
17. Moncrief T, Beck AF, Simmons JM, Huang B, Kahn RS. Single parent households and increased child asthma morbidity. *J Asthma*. 2014;51: 260–266.
18. Ardura-Garcia C, Stolbrink M, Zaidi S, Cooper PJ, Blakey JD. Predictors of repeated acute hospital attendance for asthma in children: A systematic review and meta-analysis. *Pediatr Pulmonol*. 2018;53: 1179–1192.
19. Ochoa-Avilés AM, Ochoa-Avilés C, Morillo-Argudo DA, Molina-Cando MJ, Rodas-Espinoza CR, Chis Ster I, et al. Impact of COVID-19 pandemic on asthma symptoms and management: A prospective analysis of asthmatic children in Ecuador. *World Allergy Organ J*. 2021;14: 100551.
20. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N Engl J Med*. 2016;374: 1842–1852.
21. Forno E, Gogna M, Cepeda A, Yañez A, Solé D, Cooper P, et al. Asthma in Latin America. *Thorax*. 2015;70: 898–905.
22. Alith MB, Gazzotti MR, Nascimento OA, Jardim JR. Impact of asthma control on different age groups in five Latin American countries. *World Allergy Organ J*. 2020;13: 100113.
23. Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and health care utilization in Asia-Pacific countries. *Respir Med*. 2014;108: 271–277.
24. Sastre J, Fabbri LM, Price D, Wahn HU, Bousquet J, Fish JE, et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. *World Allergy Organ J*. 2016;9: 13.
25. Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. *Medical Journal of Australia*. 2015. pp. 492–496. doi:10.5694/mja14.01564
26. Ardura-Garcia C, Vaca M, Oviedo G, Sandoval C, Workman L, Schuyler AJ, et al. Risk factors for acute asthma in tropical America: a case-control study in the City of Esmeraldas, Ecuador. *Pediatric Allergy and Immunology*. 2015. pp. 423–430. doi:10.1111/pai.12401

- 1
2
3
4 27. Cruz AA, Souza-Machado A, Franco R, Souza-Machado C, Ponte EV, Santos PM,
5 et al. The Impact of a Program for Control of Asthma in a Low-Income Setting.
6 World Allergy Organization Journal. 2010. pp. 167–174.
7 doi:10.1097/wox.0b013e3181dc3383
8
9
- 10 28. Cusack RP, Satia I, O’Byrne PM. Asthma maintenance and reliever therapy:
11 Should this be the standard of care? Ann Allergy Asthma Immunol. 2020;125:
12 150–155.
13
14
- 15 29. Abrams EM, Becker AB, Szeffler SJ. Paradigm Shift in Asthma Therapy for
16 Adolescents: Should It Apply to Younger Children as Well? JAMA pediatrics.
17 2020. pp. 227–228.
18
19
- 20 30. Abrams EM, Shaker M, Greenhawt M, Fernandes RM, Sinha I. Treatment of mild-
21 to-moderate asthma in childhood and adolescence in 2021. Lancet Respir Med.
22 2021;9: 443–445.
23
24
- 25 31. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al.
26 GINA 2019: a fundamental change in asthma management: Treatment of
27 asthma with short-acting bronchodilators alone is no longer recommended for
28 adults and adolescents. Eur Respir J. 2019;53. doi:10.1183/13993003.01046-
29 2019
30
- 31 32. Neffen H, Chahuàn M, Hernández DD, Vallejo-Perez E, Bolivar F, Sánchez MH, et
32 al. Key factors associated with uncontrolled asthma – the Asthma Control in
33 Latin America Study. Journal of Asthma. 2020. pp. 113–122.
34 doi:10.1080/02770903.2018.1553050
35
36
- 37 33. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. Clin
38 Rev Allergy Immunol. 2020;59: 78–88.
39
40
- 41 34. Wang Y, Ao G, Qi X, Xie B. The association between COVID-19 and asthma: A
42 systematic review and meta-analysis. Clinical & Experimental Allergy. 2020. pp.
43 1274–1277. doi:10.1111/cea.13733
44
45
- 46 35. Hartmann-Boyce J, Gunnell J, Drake J, Otunla A, Suklan J, Schofield E, et al.
47 Asthma and COVID-19: review of evidence on risks and management
48 considerations. BMJ Evid Based Med. 2020. doi:10.1136/bmjebm-2020-111506
49
- 50 36. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al.
51 COVID-19-related Genes in Sputum Cells in Asthma. Relationship to
52 Demographic Features and Corticosteroids. Am J Respir Crit Care Med.
53 2020;202: 83–90.
54
55
- 56 37. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al.
57 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
58 HCoV-229E replication and cytokine production by primary cultures of human
59 nasal and tracheal epithelial cells. Respir Investig. 2020;58: 155–168.
60

- 1
2
3
4 38. Schultze A, Douglas I. COVID-19 and inhaled corticosteroids—another piece in
5 an expanding puzzle. *The Lancet Respiratory Medicine*. 2021. pp. 674–675.
6 doi:10.1016/s2213-2600(21)00076-x
7
8
9 39. Papadopoulos NG, Mathioudakis AG, Custovic A, Deschildre A, Phipatanakul W,
10 Wong G, et al. Childhood asthma outcomes during the COVID-19 pandemic:
11 Findings from the PeARL multi-national cohort. *Allergy*. 2021;76: 1765–1775.
12
13 40. Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. Changes in
14 medication adherence among patients with asthma and COPD during the
15 COVID-19 pandemic. *J Allergy Clin Immunol Pract*. 2020;8: 2384–2385.
16
17 41. Romero NC, Cisneros-Caceres MJ, Granadillo E, Aragao E, Romero-Sandoval A,
18 Barbosa C, Barreto de Oliveira AL, et al. Health workers' perspectives on asthma
19 care coordination between primary and specialised healthcare in the COVID-19
20 pandemic: a protocol for a qualitative study in Ecuador and Brazil. *BMJ Open*
21 2021;11:e052971.
22
23 42. Instituto Nacional de Meteorología e Hidrología. Anuario Meteorológico Nro. 53-
24 2013. Quito, Ecuador: INAMHI; 2015.
25
26 43. Ministerio de Salud Pública. Manual del modelo de atención integral del sistema
27 nacional de salud familiar comunitario e intercultural (MAIS-FCI). Ecuador: MAIS-
28 FCI; 2012 [cited 22 Apr 2021]. Available:
29 <https://es.scribd.com/document/338645477/Manual-MAIS-MSP12-12-12-pdf>
30
31 44. Lucio R, Villacrés N, Henríquez R. Sistema de salud de Ecuador. *Salud pública de*
32 *México*. 2011;53: s177–s187.
33
34 45. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, et al. Development
35 and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy*
36 *Clin Immunol*. 2007;119: 817–825.
37
38 46. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al.
39 Development of the asthma control test☆A survey for assessing asthma control.
40 *Journal of Allergy and Clinical Immunology*. 2004. pp. 59–65.
41 doi:10.1016/j.jaci.2003.09.008
42
43 47. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring
44 quality of life in children with asthma. *Qual Life Res*. 1996;5: 35–46.
45
46 48. Fitzclarence CA, Henry RL. Validation of an asthma knowledge questionnaire. *J*
47 *Paediatr Child Health*. 1990;26: 200–204.
48
49 49. Praena Crespo M, Lora Espinosa A, Aquino Llinares N, Sánchez Sánchez AM,
50 Jiménez Cortés A. [The Spanish version of the Newcastle Asthma Knowledge
51 Questionnaire for parents of children with asthma (NAKQ). Transcultural
52 adaptation and reliability analysis]. *An Pediatr* . 2009;70: 209–217.
53
54
55
56
57
58
59
60

- 1
2
3
4 50. Franco R, Nascimento HF, Cruz AA, Santos AC, Souza-Machado C, Ponte EV, et al.
5 The economic impact of severe asthma to low-income families. *Allergy*. 2009;64:
6 478–483.
7
- 8
9 51. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic
10 reference values for spirometry for the 3-95-yr age range: the global lung
11 function 2012 equations. *Eur Respir J*. 2012;40: 1324–1343.
12
- 13 52. Association for Respiratory Technology & Physiology. ARTP COVID-19 GROUP:
14 Practical guidance for increasing Lung Function and Sleep activity during COVID-
15 19 Endemic Phase. Aug 2020 [cited 25 Jan 2021]. Available:
16 [https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVI](https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVID_Practical_Innovations_Vers1.2_final.pdf)
17 [D_Practical_Innovations_Vers1.2_final.pdf](https://www.artp.org.uk/write/MediaUploads/Standards/COVID19/ARTP_COVID_Practical_Innovations_Vers1.2_final.pdf)
18
19
- 20 53. PCRS. Position Statement Diagnostic work up of the patient presenting with
21 respiratory symptoms during the COVID-19 pandemic. In: The Primary Care
22 Respiratory Society [Internet]. 17 Sep 2020 [cited 25 Jan 2021]. Available:
23 [https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-](https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-asthma-COPD-during-COVID-19-v2-17-September-2020.pdf)
24 [asthma-COPD-during-COVID-19-v2-17-September-2020.pdf](https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-asthma-COPD-during-COVID-19-v2-17-September-2020.pdf)
25
26
- 27 54. Coronavirus & the 2nd Generation NObreath - Update. In: NObreath [Internet].
28 [cited 25 Jan 2021]. Available: [https://www.nobreathfeno.com/coronavirus-and-](https://www.nobreathfeno.com/coronavirus-and-the-2nd-generation-nobreath-update/)
29 [the-2nd-generation-nobreath-update/](https://www.nobreathfeno.com/coronavirus-and-the-2nd-generation-nobreath-update/)
30
31
- 32 55. Guevara Á, Vivero S, Nipaz V, Guaraca V, Coloma J. A Low-Cost SARS-CoV-2 rRBD
33 ELISA to Detect Serostatus in Ecuadorian Population with COVID-19. *Am J Trop*
34 *Med Hyg*. 2021. doi:10.4269/ajtmh.20-1420
35
36
- 37 56. AAAAI. Spirometry during COVID-19. In: American Academy of Allergy, Asthma &
38 Immunology [Internet]. 23 Apr 2020 [cited 25 Jan 2021]. Available:
39 <https://www.aaaai.org/ask-the-expert/spirometry>
40
41
- 42 57. Stanojevic S, Beaucage F, Comondore V, Faughnan M, Kovesi T, McCoy C, et al.
43 Resumption of pulmonary function testing during the post-peak phase of the
44 COVID-19 pandemic. *Canadian Journal of Respiratory, Critical Care, and Sleep*
45 *Medicine*. 2020. pp. 156–159. doi:10.1080/24745332.2020.1796211
46
47
- 48 58. McGowan A, Sylvester K, Burgos F, Boros P, de Jongh F, Kendrick A, et al.
49 Recommendation from ERS Group 9.1 (Respiratory function
50 technologists/Scientists) Lung function testing during COVID-19 pandemic and
51 beyond. ; 2020 [accessed 2020 Aug 31]. In: European Respiratory Society
52 [Internet]. [cited 18 Jul 2020]. Available:
53 <https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h>
54
55
- 56 59. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in
57 logistic and Cox regression. *Am J Epidemiol*. 2007;165: 710–718.
58
- 59 60. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of
60

1
2
3
4 the number of events per variable in logistic regression analysis. *J Clin Epidemiol*.
5 1996;49: 1373–1379.
6

- 7
8 61. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per
9 independent variable in proportional hazards analysis. I. Background, goals, and
10 general strategy. *J Clin Epidemiol*. 1995;48: 1495–1501.
11
12 62. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per
13 independent variable in proportional hazards regression analysis. II. Accuracy
14 and precision of regression estimates. *J Clin Epidemiol*. 1995;48: 1503–1510.
15
16
17 63. White IR, Royston P, Wood AM. Multiple imputation using chained equations:
18 Issues and guidance for practice. *Stat Med*. 2011;30: 377–399.
19
20 64. White IR, Royston P. Imputing missing covariate values for the Cox model. *Stat*
21 *Med*. 2009;28: 1982–1998.
22
23 65. Royston P, Altman DG. External validation of a Cox prognostic model: principles
24 and methods. *BMC Med Res Methodol*. 2013;13: 33.
25
26
27 66. Ahanchian H, Jones CM, Chen YS, Sly PD.
28 Respiratory viral infections in children with asthma: do they matter and can
29 we prevent them? *BMC Pediatr* 2012;12:147.
30
31
32 67. Influenza and other respiratory viruses.
33 <https://www.paho.org/en/topics/influenza-and-other-respiratory-viruses>
34
35
36
37

38 **Author statement:** Study design – PJC, AAC, NR, MB, MP, CA-G; study conduct – DM,
39 SM-B, AO, MEC, CR, AM, KA, AR, CF, JA, KS; manuscript drafting – PJC, DM, SM-B;
40 statistical analysis plan – ICS; manuscript editing and review – all authors.
41
42
43
44

45 **Funding:** This work is based on the Asthma Attacks Causes and Prevention Study in
46 Urban Latin America which is funded by the National Institute of Health Research
47 [NIHR] under the Global Health Research Programme [grant 17/63/62]. Additional
48 financial support was provided by the Corporación Ecuatoriana para el Desarrollo de
49 la Investigación y la Academia CEDIA [N° CEPRA-XV-2021-03].
50
51
52
53
54
55

56 **Competing Interests statement:** The authors declare no competing interests.
57
58
59
60

1
2
3
4 **Patient and public involvement statement:** There was no patient or public
5 involvement in the design or conduct of this study. Results of tests are being provided
6 at the time of testing and the study population is being informed of study results
7 through periodic leaflets, a website, social media texts and videos, and study group
8 online meetings.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

152x107mm (144 x 144 DPI)




Figure 2

408x217mm (160 x 160 DPI)